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ABSTRACT 
 
Serratia species are an important source of antimicrobial compounds with numerous studies 
concerning their production of secondary metabolites with applications in medicine, 
pharmaceutics and biotechnology. This study continued investigations on the antibacterial 
activity of an environmental isolate of Serratia plymuthica. This activity could be detected 
on agar plates against Gram-positive bacteria.  
A previous study reported the isolation of KmR transposon mutants deficient in the activity 
identified on agar plates but appeared to possess another activity secreted in liquid media. 
Those mutants had Tn5 insertions into genes encoding polyketide synthases (PKSs). The 
multiple antibacterial activities of S. plymuthica indicate the production of antimicrobials 
that can diffuse into aqueous environments in addition to the ones closely bound to the outer 
cell surface and secreted into solid mediums.  This raised the question about the relationship 
between the two activities, were they distinct or related? 
This study investigated the secreted antibacterial activity of S. plymuthica using transposon 
mutagenesis to create mutants deficient in the secreted antibacterial activity and to identify 
the genes involved in antibacterial production. Cultivation parameters such as; culture 
medium, aeration and temperature had a clear impact on the production of the secreted 
antibacterial activity. Growing S. plymuthica in MRS broth at 16oC for 48h-72h produced 
the highest amount of inhibitory activity detected in the CFCS.  The secreted antibacterial 
activity was thermo-stable and remained active even after sterilization (121°C/15mins) and 
was insensitive to methanol, Proteinase K, Tween and pH. However, the antibacterial activity 
faded after few days even when stored at (4oC). The antibacterial activity was bactericidal 
and targeted a sub-set of Gram-postive bacteria especially Bacillaceae. The CFCS 
precipitated in the presences of solvents such as methanol, Tris-buffer and Tween.  Structural 
characterization of the antibacterial compound(s) was confirmed via NMR and COSY 
spectrometry and showed the presence of two polyketide compounds resembling the 
macrolide antibiotics erythromycin and rapamycin produced by type I PKSs. Erythromycin 
and rapamycin are anti-bacterial and immune-suppressant compounds. 
 Results of this study indicate that the secreted antibacterial activity of S. plymuthica is 
synthesized by PKSs that are distinct from other known Serratia PKSs. Results are also 
consistent with the possibility of S. plymuthica possessing separate biochemical pathways 
leading to two distinct antibacterial activities or a branched biochemical pathway. However, 
future studies are needed to reveal if the genes responsible for the two activities are in 
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separate genomic locations and regulated in different manners to prove that the strain 
possesses two separate biochemical pathways leading to the two distinct activities. Further 
work is needed to unlock these unanswered questions. This includes genomic studies in order 
to identify new secondary metabolites with future importance that might be produced by this 
novel strain of S. plymuthica.  
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Figure 4.16:  Partial sequencing of the flanking genomic DNA of KmR recombinant 
plasmids obtained in this study   was done using primers TPNRL17-1 and TPNRL13-2 
that anneal to the origin of replication and the KmR gene of the transposon. 
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Figure 4.17: Amino acid sequence of Polyketide synthase obtained from Blastx analysis 
(NCBI) of the flanking region of transposon insertion of mutant M426 using TPNRL17-
1 primer in a comparison with the database. 
100 
Figure 5.1: Demonstration of the end-product of concentrating the CFCS. Concentrating 
the CFCS via freeze-drying resulted in the production of a powder-like material (A) 
which was re-suspended in 2 ml sterile deionized water and named concentrated culture 
supernatant CCS (B). 
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Figure 5.2:  Demonstration of the antibacterial activity of the CCS against the Gram-
positive strain (F); NA (RT/24h). A; zone of inhibition (12.0 mm) in diameter produced 
by the CCS. B; a nutrient agar plate showing lack of activity produced by the 
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concentrated negative control (NB broth only) against the Gram-positive strain. This 
image is a representative image of 3 replicates.                                                                                                  
Figure 5.3: Demonstration of the result of concentrating the CFCS via rotary evaporation 
and the production of a brown gel-like material which was collected from the rotary bulb 
and re-suspended in sterile deionized water (2 ml). 
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Figure 5.4: The activity of the positive controls used in organic solvent extraction method 
against the Gram-positive strain (F); NA (RT/24h). A; a zone of inhibition (12.0 mm) in 
diameter produced by the insoluble fraction of the positive control. B; a zone of inhibition 
(10.0 mm) in diameter produced by soluble fraction of the positive control. This image 
is a representative image of 3 replicates. 
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Figure 5.5: The activity of the soluble fraction of the CCS against the Gram-positive 
strain (F). This image is a representative image of 3 replicates. 
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Figure 5.6: The activity of the insoluble fraction of the CCS against the Gram-positive 
strain (F). This image is a representative image of 3 replicates. 
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Figure 5.7: The NMR spectrum of the secreted antimicrobial compound(s) have two 
dimensions: the x axis corresponding to the frequency (ppm) and the Y axis 
corresponding to the intensity. The peak at 2.5 ppm is the DMSO signal. Samples were 
named as follows: [sample 1; soluble fraction of the CFCS, sample 2; insoluble fraction 
of the CFCS, sample 3; soluble fraction of the CCS and sample 4; insoluble fraction of 
the CCS]. The NMR spectrum of sample 3 showed peaks with high intensity at 3-5 ppm 
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structure. The NMR spectrum of sample1 showed peaks at 1-1.5 ppm and 3-3.5 ppm 
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Figure 5.8: NMR analysis of the secreted antimicrobial compound(s) in sample 1 (soluble 
fraction of the CFCS) and sample 3 (soluble fraction of the CCS). Upper graph; modular 
organization of the secreted antibacterial compound showing type I PKSs structure 
resembling erythromycin and incomplete modular organization of a second antibacterial 
compound similar to rapamycin. Lower graph; superimposed spectra of sample 1 (blue 
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line) and sample 3 (red line) showing a peak at 2.5 ppm corresponding to the DSMO-d6, 
a peak at 0.5-1.5ppm corresponding to methyl units, a peak at ~3-5 ppm corresponding 
to hydroxyl units and unsaturated moieties at 6-8.5 ppm. 
Figure 5.9: Results of COrrelation SpectroscopY COSY of sample 3 (soluble fraction of 
the CCS) which confirmed a correlation between CHOH moieties with the alkyl units as 
shown by the arrows that correspond with cross peaks observed in the spectrum 
highlighted with the same colour as the arrows. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Microbial natural metabolites  
 
For many years now, microorganisms have been a fascinating area of study. Researchers have 
realized the importance of these tiny microbes for their ability to produce various useful natural 
metabolites and compounds with uncultured bacterial species being a rich source of bioactive 
molecules (Genilloud, 2014; I´oca et al., 2014). Microbial secondary metabolites are low 
molecular weight substances produced at later stages of microbial growth. Production can also be 
triggered by extrinsic stimuli and the availability of nutrients like nitrogen, phosphorous and 
carbon (Ruiz et al., 2010; Masschelein et al., 2015a). Natural metabolites represent an enormous 
group of organic compounds that do not play essential roles in the normal growth and development 
of the producing microorganisms but merely confer a selective advantage in complex microbial 
communities as a biological defense mechanism against predators (Lorente et al., 2014; Hellberg 
et al., 2015; Hibbing et al., 2010). The biosynthesis of bacterial secondary metabolites involves 
multiple enzymatic pathways and reactions brought about by structural diversity which contribute 
to their highly specific mechanisms of action (Cragg & Newman, 2013). Secondary metabolites 
include isoprenes, oligosaccharides, peptides, polyketides, β-lactam rings and aromatic 
compounds (Masschelein et al., 2013; Matilla et al., 2016b; Müllera & Wink, 2014). 
The majority of antibiotics are derived from bacterial metabolites and soil bacteria including; 
Streptomyces, Actinomycetes and Mycobacteriaceae which are the main source of novel secondary 
metabolites with more than 20,000 products having been characterized including anti-helmintic, 
immuno-suppresant, cytotoxic, anti-inflammatory, anti-malaria and antiviral compounds (Gerc et 
al., 2012; Abel et al., 1999; Peláez, 2006). Bacillus species are major producers of antimicrobials, 
such as bacteriocin. The bacteriocin of B. licheniformis holds potent activity against Gram-positive 
bacteria (Manivasagan et al., 2014; Matilla et al., 2015). Streptomyces bioactive compounds 
include dithiolopyrrolones and Bleomycin (Trautman & Crawford, 2016; Sanchez et al., 2010 b). 
Research revealed the production of the antibiotic Actinorhodin by Streptomyces coelicolor which 
exhibit potent activity against Gram-positive bacteria (Rahman et al., 2010; Katz & Baltz, 2016; 
Mak et al., 2014). The Gram-negative bacteria Pantoea agglomerans produces the pseudo-peptide 
antibiotic Andrimid which displays broad spectrum antibacterial activities and anti-cancer 
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properties. Mycobacteriaceae produce the antibiotic elansolid with inhibitory activity against 
Methicillin-resistant S. aureus (Müllera & Wink, 2014; Pidot et al., 2014). Aspergillus nidulans 
produces the anti-tumour compound terrequinone A while, thiolactomycin isolated from 
Nocardiaha shows anti-malarial and antibacterial activity (Yurkovich et al., 2017; Peláez, 2006).  
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1.2 History of antibiotics  
 
The history of antibiotics began in 1928 when Alexander Fleming observed that the growth of a 
plate of Staphylococcus aureus had been inhibited by a mold contamination. This mold was later 
identified as Penicillin notatum (Kümmerer, 2009; Saleem & Iqbal, 2015). This discovery was one 
of the most influential moments in human kind history and in the following years; penicillin was 
used as the first weapon to combat the most common infectious diseases in that era like pneumonia, 
gonorrhea and rheumatic fever. The so called ‘‘golden age’’ of antibiotics was mainly from the 
1940s to the 1960s during which most of the major classes of antibiotics were produced. These 
include β-lactams, aminoglycosides, tetracyclines, macrolides and chloramphenicol (Wencewicz, 
2016; Masschelein et al., 2015a). The majority of current drugs are based on the chemical 
modification of existing antibiotics with only few being fully synthetic like fluoroquinolones. An 
antibiotic can be defined as a bio-chemical compound produced by a microbe which kills or 
inhibits the growth of other microorganisms in low concentrations (Challinor & Bode, 2015; 
Davies & Davies, 2010; Kasanah & Hamann, 2004). No one can deny the importance of 
antibiotics, they are used to treat a wide range of bacterial infections and used as antitumor and 
anti-parasitic agents. They are extremely essential components of modern medicine, especially in 
intensive care, organ transplantation, cancer chemotherapy and surgical procedures. Antibiotics 
are also used in agriculture, aquaculture and in food processing (Marti et al., 2014; Meek et al., 
2015; Pires et al., 2017). 
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1.3 Antibiotic Classification 
 
Antibiotic classification is based on various chemical properties. These include, mechanism of 
action, cellular components they affect and whether they induce cell death (bactericidal drugs) or 
merely inhibit cell growth (bacteriostatic drugs) (Kohanski et al., 2010; Martinez, 2014; Dwyer, 
2015). Research revealed that in reality pure classes of antimicrobial compounds (bactericidal/ 
bacteriostatic) do not exist and if so called “bactericidal” agents fail to kill every microorganism 
within a defined period then these agents will be called bacteriostatic (Pankey& Sabath, 2004; 
Rodloff et al., 2008). The most important cellular targets of antibiotics are shown in Figure 1.1 
and include DNA replication, cell wall synthesis, protein synthesis and metabolic functions 
(Procópio et al., 2012; Lewis, 2013). 
 
1.3.1 Protein synthesis inhibitors  
 
1.3.1.1 Aminoglycosides and Tetracyclines 
 
Aminoglycosides are one of the oldest groups of antibiotics, with streptomycin being the first 
member to be discovered in 1944. Aminoglycosides are hydrophilic compounds and consist of 
amino-sugars connected through glycosidic bonds. Examples include kanamycin, gentamicin and 
streptomycin (Hoerr et al., 2016; Procópio et al., 2012). This group of antibiotics is still used today 
in clinical practices despite their nephro-toxic side effects. They are bactericidal with broad-
spectrum activity against aerobic Gram-positive and Gram-negative bacteria (Chellat et al., 2016). 
They target the 16S rRNA of the 30S–50S ribosome junction and disturb the stability of t-RNA 
binding to ribosomes which leads to the misreading of genetic code and the incorporation of 
incorrect amino acids into peptide chains. These abnormal proteins affect the bacterial cell 
membrane permeability leading to an increase in aminoglycoside uptake (Fourmy et al., 1996; Fair 
& Tor, 2014). Resistance occurs through modification of the target ribosome by methylation and 
by the action of enzymes like aminoglycoside N-acetyltransferases and efflux pumps (Mak et al., 
2014; Katz & Baltz, 2016). Tetracyclines are bacteriostatic broad-spectrum antibiotics. In 1945, 
chlortetracycline was the first drug to be discovered within this group but, it was not until 1948 
that it was used clinically (Katz & Baltz, 2016). Other examples include, oxytetracycline, 
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clomocycline and methacycline. The chemical structure of this class consists of an octa-hydro-
tetracene skeleton. This group is active against Gram-positive and Gram-negative bacteria, 
Vancomycin-resistant Enterococcus, Clostridium difficile and protozoan parasites. Tetracyclines 
display only minor side effects which make them favorable in treating human bacterial infections 
(Procópio et al., 2012; Chellat et al., 2016). Tetracyclines act by penetrating the outer bacterial 
cell membrane into the cytoplasm, affecting the metal-ion concentration and causing an increase 
in pH. This creates a metal-ion/tetracycline complex which inhibits the binding of the aminoacyl 
tRNA to its designated ribosomal site. Resistance occurs via ribosomal modification induced by 
the tet and otr genes, inactivating enzymes and efflux pumps (Nguyen et al., 2014; Chopra & 
Roberts, 2001). 
 
1.3.1.2 Chloramphenicol, Macrolides and Lincosamides 
 
Chloramphenicol is a bacteriostatic antibiotic with broad spectrum activity. This class of 
antibiotics act on the 50S ribosomal subunit and prevent amino acid transfer by inhibiting peptidyl 
transferase and protein synthesis (Rahal et al., 1979).  
As chloramphenicol, macrolides also act on the 50S ribosomal subunit and inhibit the synthesis of 
peptide chains. Macrolides are macro-cyclic lactones with deoxy-sugars. The first macrolide to be 
discovered was Erythromycin in 1949 isolated from Actinobacteria (Saleem & Iqbal, 2015). 
Others include tylosin and spiramycin. Macrolides display broad-spectrum activity against Gram-
positive and Gram-negative bacteria. Macrolides are bacteriostatic but display bactericidal activity 
against Streptococcus pneumoniae and Haemophilus influenzae. Resistance occurs via Mono-
methylation of rRNA (Katz & Baltz, 2016; Mak et al., 2014).  
Lincosamides include Lincomycin, Clindamycin and Pirlimycin. These antibiotics inhibit protein 
synthesis by binding to the 50S ribosomal subunit with the inhibition of peptidyl transferases. 
Lincosamides are effective against anaerobic species and Gram-positive bacteria and considered 
both bactericidal and bacteriostatic (Leclercq, 2002; Fair & Tor, 2014). 
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1.3.2 Cell Wall Synthesis Inhibitors 
 
1.3.2.1 Glyco-peptides and Beta-lactam antibiotics 
 
Glyco-peptides and Lipo-glyco-peptides antibiotics include Vancomycin, Teicoplanin, and 
Avoparcin. Glyco-peptides are known as “Last resort antibiotics” in human medicine due to their 
highly toxic side effects. Glyco-peptides are bactericidal with narrow spectrum activity but 
effective against Gram-positive bacteria. Glyco-peptides interfere with penicillin-binding protein 
enzymes like transpeptidases and inhibit transglycosylation and transpeptidation which contribute 
to cell wall synthesis leading to bacterial cell death. Resistance occurs when the C-terminal D-
alanyl-D-alanine of lipid II replaces the D-alanyl-D-lactate which in turn decreases the antibiotic 
affinity to interact to its cell wall target (Marcone et al., 2010; Chellat et al., 2016). Regarding 
Beta-lactam antibiotics, they are a group of compounds with diverse molecular structure but share 
a common four-membered β-lactam ring. The first Beta-lactam antibiotic to be discovered was 
benzyl-penicillin (Penicillin G). Other examples include, methicillin, ampicillin and amoxicillin 
(Saleem & Iqbal, 2015; Dantas & Sommer, 2014). They are bactericidal with low toxic side effects 
and broad-spectrum activity against various bacterial infections and diseases like anthrax, tetanus, 
streptococcal infections, UTI and enteritis (Kong et al., 2009; Katz & Baltz, 2016).  
β-lactam antibiotics are inhibitors of cell wall synthesis. This occurs when the beta-lactam ring 
structure binds to penicillin-binding proteins located in the cell membrane which leads to autolysis 
and bacterial cell death (Fair & Tor, 2014). Resistance mechanisms involve the modification of 
cellular membrane channels and preventing the antibiotic from binding to penicillin-binding 
proteins also efflux pumps that eject the antibiotic out of the cell and antibiotic inactivation via 
hydrolysis of the β-lactam ring mediated by β-lactamase enzymes (Kohanski et al., 2010). 
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1.3.3 Nucleic acid synthesis inhibitors 
  
1.3.3.1 Fluoroquinolones, Rifamycins and Quinolones 
 
Fluoroquinolones and Rifamycins are bactericidal antibiotics that inhibit nucleic acid synthesis by 
binding to DNA gyrase and topoisomerase IV leading to a defect in DNA and cell death. 
Fluoroquinolones include, Enrofloxacin and Ciprofloxacin. Rifamycins include Rifampin, and 
Rifabutin. Resistance is due to mutations in topoisomerase IV and DNA gyrase (Hooper, 2001; 
Zhanel et al., 1999). 
 Quinolones are bactericidal antibiotics with broad-spectrum activity against Gram-positive and 
Gram-negative bacteria. These antibiotics are used in the treatment of skin, lung and urinary tract 
infections. This group of antibiotics target DNA replication. The topology of DNA is controlled 
by DNA Gyrase which has an important function in DNA and mRNA synthesis (Dantas & 
Sommer, 2014; Saleem & Iqbal, 2015). Quinolones create a complex with topoisomerase and 
prevent DNA replication and affect nucleic acid metabolism leading to cell death. Resistance 
occurs through target modification by mutations of the genes gyrA and parC (Pankey & Sabath, 
2004; Kohanski et al., 2010). 
 
1.3.4 Inhibitors of metabolic functions 
 
1.3.4.1 Sulfonamides and Diaminopyrimidines 
 
Sulfonamides and Diaminopyrimidines are bacteriostatic antibiotics that inhibit folic acid 
synthesis by interfering with the function of the enzyme dihydropteroate synthetase from adding 
paraaminobenzoic acid to the structure of folic acid. Sulfonamides include sulfadiazine and 
sulfamethoxazole (Kolaczek et al., 2014; Huovienen, 1987). Both groups display broad-spectrum 
activity against Gram-positive and Gram-negative bacteria and protozoal parasites. Sulfonamides 
resistance has been recorded in Gram-negative bacteria like some strains of Escherichia coli that 
contain plasmid encoded resistance genes namely sul1, sul2, and sul3 (Arabi et al., 2015; 
Huovinen et al., 1995). 
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Figure 1.1:  Main bacterial cellular targets of antibiotics (Lewis, 2013). 
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1.4 Antibiotic resistance  
 
Infectious diseases are the second leading cause of death killing 3 million people each year around 
the world. The rapid development of antibiotic resistance is one of the biggest medical threats of 
modern times. The emergence of community and hospital-acquired infections of resistant 
pathogens (Figure 1.2) imposes serious threats in community and hospital settings (Navarri et al., 
2016; Spížek et al., 2010; Sanchez et al., 2010a). Examples include methicillin and vancomycin 
resistant Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae, Neisseria 
gonorrhoeae, Acinetobacter baumannii, Mycobacterium tuberculosis (Barrett & Barrett, 2003; 
Dancer, 2008). Infections caused by penicillin resistant Streptococcus pneumoniae is a public 
health concern in Qatar causing community-acquired pneumonia, bacteremia, meningitis and otitis 
and mostly affecting the elderly and young children (Elshafie & TajAldeen, 2016).  
Gram-negative opportunistic pathogens like E. coli and P. aeruginosa are extremely worrying 
since they are the cause of common bacterial infections affecting human health with these strains 
being highly resistant to antibiotics (Hoerr et al., 2016). In recent years, the prevalence of 
untreatable gonorrhea infections become of great concern due to the emergence of a new strain of 
Neisseria gonorrhoeae that is extremely resistant not only to the first-line treatment of antibiotics 
but to extended-spectrum cephalosporins (Unemo & Nicholas, 2012).  
More than 70% of bacterial pathogens causing infectious diseases have become resistant to at least 
one of the drugs used in the treatment of these infections. Resistance has rapidly developed from 
resistance to single classes of antibiotics to multidrug resistance and extreme drug resistance 
(Davies & Davies, 2010). Examples include multi-drug resistant Clostridium difficile and the rise 
of hospital acquired Acinetobacter baumanii infections affecting mainly immune-compromised 
patients in intensive care units (Marti et al., 2014).  
In 2013, the World Health Organization WHO reported more than 400,000 new cases of 
multidrug-resistant tuberculosis as well extensively drug-resistant tuberculosis. Antibiotic 
resistance is a major challenge to treat infectious diseases, not to mention the enormous clinical 
and financial burden on health care systems (Blair et al., 2015). Patients affected by infections 
caused by drug-resistant bacteria are at risk of serious health problems and high consumption of 
medical resources (Fischbach & Walsh, 2009).  Fortunately, according to the European 
Antimicrobial Resistance Surveillance Network EARS-Net, in recent years a dramatic change in 
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some of the resistant strains has been noticed in which improved hospital practices, such as 
cleaning and disinfection of surfaces, resulted in a decrease of transmission of MRSA and VRE 
between patients, emphasizing the importance of good housekeeping in healthcare facilities to 
reduce the risk of infections. However, there have been reports of increased resistance in other 
bacterial strains like Acinetobacter with notable high mortality rates (Wang et al., 2013; Fair & 
Tor, 2014; Lee et al., 2013). 
 
 
 
Figure 1.2: Examples of the most common resistant bacterial strains causing community and acquired infectious 
disease (Fischbach & Walsh, 2009). 
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1.4.1 Origin of antibiotic resistance  
 
The emergence and spread of antibiotic resistance and antibiotic resistance genes is a major 
modern dilemma affecting various countries around the world. A lack of awareness of 
antimicrobial resistance among health care workers and patients allow this dilemma to propagate. 
Effective antimicrobial prescribing is a challenge as well as creating a balance between the dosage, 
duration of treatment and severity of the disease. More than 90% of antibiotics in Europe are 
prescribed to non-hospitalized patients, 46% in Brazil and 100 % in Nigeria and Sudan. In Qatar, 
35 % of prescribed medications from private clinics were for antibiotics. Access to nonprescribed 
antibiotics also include purchases over the counter and online market companies (Marti et al., 
2014; Davies & Davies, 2010; Keown et al., 2014).  
Inadequate investments in the research of novel antibiotics and treatments as well as inappropriate 
practices (Figure 1.3) all contributed to selection pressure and the spread of resistant genes into 
human pathogens as demonstrated by the presence of the same resistant genes of soil bacteria in 
human pathogens. Examples include, patient self-medication, non-compliance with prescribed 
dosages (Bell et al., 2014; Black et al., 2014). 
Some studies claim that levels of antimicrobial resistance are proportional to antibiotic 
consumption with observed resistance to penicillin and streptomycin shortly after their 
introduction in clinical practices. The release of antibiotics such as vancomycin, and the bio-
chemical changes in natural ecosystems, altered the biological dynamics of microorganisms and 
lead to the selection of resistance (Elshafie &TajAldeen, 2016; Allen et al., 2014; Martinez & 
Baquero, 2014).  
The dissemination of resistant bacteria had major effects on animal husbandry and even minute 
amounts of antibiotics can inflict a selective pressure on clinical bacterial strains. In Europe, it is 
prohibited to use antibiotics as growth promoters, although some like streptomycins are still used 
in crop growing and bee-keeping. Current sensitive bacterial pathogens can predominate in 
bacterial communities even if the designated antibiotic is absent emphasizing the absence of 
reversibility in clinical settings (Bell et al., 2014; Kümmerer, 2009; Saleem & Iqbal, 2014). 
 Poor sanitary conditions support the growth of pathogenic bacteria and the spread of antibiotic-
resistant pathogens and their dissemination through water bodies which might reach farms and 
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wild animals (Wang et al., 2013; Yang et al., 2014). Antibiotic-resistant bacteria have been 
cultured from numerous rivers around the world which originated from water treatment plants and 
sewage systems. Water samples isolated from New Delhi in India, revealed the presence of 
bacterial antibiotic resistance strains as a result of contamination of water supplies by human 
faeces; emphasizing the need for appropriate treatment systems to prevent the spread of antibiotic 
resistance. Antibiotic resistance microorganisms and antibiotic resistance genes have been 
detected in seawater, beach sand, sediments and drinking water (Moskot et al., 2012; Marti et al., 
2014; Tello et al., 2012). 
Selection of resistant bacteria can even occur at low antibiotic concentrations similar to those 
found in some aquatic environments which can lead to antibiotic resistance. Marine bacteria 
isolated from the Baltic Sea have been found to be resistant to several antibiotics including 
kanamycin, ampicillin, chloramphenicol and tetracycline (Meek et al., 2015). Persistent selective 
pressure from antibiotic residues in wastewater and the presence of various species of 
microorganisms in activated sludge (AS) contribute to horizontal gene transfer of antibiotic 
resistant genes between different microbial communities mediated by mobile genetic elements 
such as plasmids and transposons. Antibiotic resistant bacterial strains derived from landfill 
disposal of sludge can disseminate into ground water and soil and remain in those environments 
even in the absence of antibiotic selection. Bacterial pathogens such as Aeromonas have been 
detected in sewage treatment with tetracycline and aminoglycoside resistance genes (Yang et al., 
2014; Marti et al., 2014).  
 
1.4.2 The resistome 
 
Antibiotic resistance is a natural phenomenon and can exist even in the absence of antibiotics. 
Studies suggest that the resistome is the source of pathogenic resistance genes which is a natural 
phenotype found in almost all bacterial species (Graham, 2015; Jiang et al., 2017; Cox & Wright, 
2013). Microbial communities have been on earth for billion years and antibiotic resistance genes 
have been around even before the introduction of antibiotics. These natural resistance genes protect 
their producers from the bioactive compounds they produce (Fair & Tor, 2014; Genilloud et al., 
2014). Antibiotic resistance can also arise from chromosomal gene mutations and genetic transfer 
between bacterial species via horizontal gene-transfer HGT which allows bacteria to acquire 
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antibiotic resistance through conjugation with the help of plasmids and transposons, through 
transformation and acquisition of naked DNA from the environment and through transduction by 
bacteriophages. Additional resistance mechanisms include efflux pumps in the bacterial membrane 
that eject antibiotics out of the cell, exclusion of antibiotics by the cell membrane, intra-cellular 
modification and deactivation of antibiotics (Allen et al., 2014; Marti et al., 2014; Kasanah & 
Hamann, 2004). 
 
 
 
Figure 1.3: Common causes of antibiotic resistance. A; over-prescription of antibiotics, B; use of antibiotics in 
agriculture and fish farming, C; inappropriate sanitation practices and personal hygiene, D; lack of new antibiotics 
discoveries. Adapted from https://www.cdc.gov/globalhealth/infographics/antibiotic_resistance_global_threat.htm 
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1.5 Prevention and control strategies 
 
For many years, antibiotic resistance has been considered a ‘problem of individual patients’ and 
all efforts were focused on the prevention of acquisition of resistance during therapy. It was not 
until recent years that antibiotic resistance was recognized as a ‘problem of hospitals’ and specific 
‘antibiotic policies’ were proposed to decrease local selection of resistant organisms and to prevent 
patient-to-patient transmission. Hand hygiene can be used to reduce antimicrobial pressure in the 
community. Social media can promote hand hygiene activities and behavior change. Hand hygiene 
improvement strategies include, the application of alcohol-based hand-rub in hospitals, work 
places and schools as well as implementing compliance monitoring and feedback (Pires et al., 
2017; Baquero et al., 2014).  
Despite the fact that antibiotic resistance is a public health concern, the surveillance for this 
phenomenon in environmental settings is limited which might be due to the fact that antibiotic 
concentrations in non-clinical settings are very low therefore it is the deployment of antibiotics in 
a clinical setting that is crucial and emphasizing  the importance of applying combined-synergistic 
therapy in enhancing the control of resistance and treatment efficiency (Bollenbach, 2015; 
Gammon, 2014). Policy makers; governments, regulatory bodies, hospital administrators and 
public health experts have a responsibility to raise awareness and integrate solutions to 
antimicrobial resistance. International groups and agencies including WHO, Centers for Disease 
Control and Prevention (CDC) and World Health Assembly emphasized the need for 
implementing immediate global actions against antimicrobial resistance; as the number of 
pharmaceutical companies is declining, human and financial burden of antimicrobial resistance is 
rising (Keown et al., 2014; Marti et al., 2014). These agencies proposed numerous solutions with 
many countries adopting new strategies to ensure the appropriate use of antibiotics through 
responsible prescription so that antibiotics are only used when indicated. An appropriate use of 
existing antibiotics is a must to ensure long term effective treatment for bacterial infections. It 
should be noted that the use of antibiotics as growth-promoters in animal farming has been banned 
in Europe since 2006 (Bell et al., 2014; Meek et al., 2015). Potential prevention approaches 
include, prolonging the therapeutic life of current antimicrobials via drug cycling; replacing an 
antimicrobial belonging to one class with one or more belonging to different classes. Studying the 
possibility of reducing the presence of antibiotic resistant genes in wastewater and the development 
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of vaccines against nosocomial infections (Holmes et al., 2016; Bennett, 2008). To prevent a 
global human threat, it is imperative to discover new sources for the production of novel 
antibacterial compounds (Cox & Wright, 2013). There are various challenges facing microbial 
natural drug discovery. Examples include: (1) unculturable microbial derived environmental 
samples, (2) failure to identify or activate small molecular bioactive metabolites from silent 
bacterial genetic pathways, (3) reduced bioactivity of natural compounds post-initial screening or 
low stability which hinder their applications as clinical drugs and (4) probability of toxicity to the 
patient (Challinor & Bode, 2015; Trautman & Crawford, 2016).   
 
1.6 The Marine Environment 
 
For centuries, humans have realized the many bioactive properties of the sea and its inhabitants. 
The marine environment is a complex ecosystem with oceans covering 70% of the world's surface 
and includes open-ocean ecosystems, thermal vent ecosystems, kelp forests, mangroves and coral 
reefs (Titilade & Olalekan, 2015; Kasanah & Hamann, 2004). The marine environment holds 
fascinating biodiversity of life forms with more than 400,000 species including, fish, tunicates, 
ascidians, corals, bryozoans, mollusks, sea slugs, sponges, algae and bacteria (Doshi et al., 2011; 
Abad et al., 2011; Darabpour et al., 2010). 
The marine environment, also called the “Medicine chest of the new millennium”, is an untapped 
source of novel compounds of great diversity. Various screening programs were developed 
worldwide with the aim of isolating new compounds and biomolecules with more than 15,000 
natural compounds having been discovered to date (Penesyan, 2010; Debbab et al., 2010). 
The aquatic environment is the home of numerous bioactive molecules and natural metabolites 
such as; proteins, peptides, polysaccharides, sterols, antioxidants, polyunsaturated fatty acids, 
polyphenols, probiotics, terpenoids, enzymes, vitamins, minerals and pigments which makes this 
fascinating environment a precious source of both economic and scientific importance (Simmons 
et al., 2005; Biswas et al., 2016). Squalamine is an amino-sterol drug from the dogfish shark with 
strong antimicrobial and anti-cancer activities (Skropeta & Wei, 2014). Fish and related products 
are a major source for the food industry and provide 16% of the world’s protein requirements and 
are rich of proteins, fatty acids, minerals and vitamins (Donia & Hamann, 2003). 
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Enzymes derived from marine organisms have various applications and have been used for years 
in biotechnology due to their high activity and salt tolerance. Marine enzymes include lipase, 
chitinolytic enzymes and transglutamase. Marine compounds are a promising source of novel 
drugs with various applications proven to be active against cancer cell lines, HIV and encompass 
anti-bacterial, anti-viral, anti-fungal, anti-protozoal, anti-tuberculosis and analgesic activities 
(Dufourcq et al., 2013; Colwell, 2002; Mayer et al., 2010). 
It is widely believed that the unique properties of marine organisms in comparison with terrestrial 
ones is largely due to the complex marine environmental niches they inhabit (Ruiz et al., 2010). 
These marine niches are characterized by extreme conditions including physio-chemical and 
biological properties that favor the production of diversely active secondary metabolites and the 
production of novel compounds as a means of adaptive survival mechanism to the hostile marine 
habitat (Suleria et al., 2015; Abad et al., 2011). Marine microbes survive extreme conditions in 
the absence of light, low levels of oxygen and extremely high pressure. Also, anaerobic conditions 
and below 0◦C temperatures in the deep-sea and highly acidic conditions with temperatures over 
100◦C in hydrothermal vents not to mention competing for space and marine fouling (Donia & 
Hamann, 2003). All these factors have contributed to the production of diverse array of bioactive 
metabolites (Katz & Baltz, 2016; Doshi et al., 2011). Some of these natural products have no actual 
metabolic functions within the producing organisms and are more of a protective agent against 
predators like the non-protein (palytoxins) produced by dinoflagellates which cause shellfish 
poisoning (Colwell, 2002).  
 
1.6.1 Marine invertebrates 
 
Marine invertebrates encompass a diverse group of inhabitants including, sponges, tunicates, 
bryozoans and molluscs. Extracts isolated from marine invertebrates can have a wide range of anti-
pathogenic properties mainly, antibacterial, antiviral, anti-helminth and anti-fungal (Abad et al., 
2011; Skropeta & Wei, 2014). 
Shrimp and krill encompass omega-3 fatty acids. The health benefits claimed for products of these 
organisms are various and include treatments for osteoporosis, Paget’s disease, reducing the risk 
of cardiovascular problems and neurodevelopment. Other benefits include the management of 
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hypertension, arthritis, total blood lipids and improving Vitamin A levels (Donia & Hamann, 
2003).  
Marine sponges such as; Theonella swinhoei are of great importance due to their ability to 
biosynthesize secondary metabolites like; polyunsaturated fatty acids, peptides, alkaloids, minerals 
and carotenoids which are active against Leishmania, Neisseria gonorrheae, Mycobacterium 
tuberculosis, Listeria monocytogenes, Candida albicans, herpes simplex and HIV (Wietz et al., 
2013; Jamal et al., 2006). Also, they are effective anti-cancer agents, and some hold anti-diabetic 
properties (Laport et al., 2009). Studies speculate that bacterial strains closely associated with 
sponges are the true source of these properties (Manivasagan et al., 2013; Gammon, 2014).  
Marine snails possess antimicrobial peptides and peptide cono-toxins which are active against fish 
and sea predators and Gram-positive and Gram-negative bacteria. Ascidians produce a diverse 
array of metabolites with anticancer properties such as the compound Didemnin B isolated from 
the ascidian Trididemnum solidum (Dolashka et al., 2011; Grabley & Thiericke,1999). Bioactive 
peptides isolated from fermented blue mussels and oyster sauces have been found to significantly 
decrease hypertension and amino acids of marine molluscs can improve skin wound healing. 
Bryostatins are polyketides produced by marine bryozoans and demonstrate antagonistic activity 
against predatory fish. A clinically important analogue of these polyketides is the anticancer drug 
Bryostatin 1 which exhibits potent cytotoxic activities (Donia & Hamann, 2003; Ridley et al., 
2008). 
 
1.6.2 Marine algae 
 
For centuries, marine algae and seaweeds have been used as a food source, in traditional medicine 
and cosmetics. Marine algae possess strong antioxidant properties and an excellent source of 
nutrients for human health (Cavallo et al., 2013). They are rich in β-carotene, polysaccharides, 
iron, manganese, zinc, phenolic compounds, minerals, antioxidants, proteins and polyunsaturated 
fatty acids (El Gamal, 2010). Marine algal metabolites are diverse and include macrolides, 
proteins, polyketides, terpenes and fatty acids. These compounds can have potent antiviral, 
antibacterial and anti-parasitic activity (Gammone et al., 2014). 
Red algal species Sphaerococcus coronopifolius are strong producers of antibacterial compounds 
like Diterpene. Anti-plasmodial activity has been detected in methanolic extracts of marine 
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seaweeds extracted from the west coast of India (Donia & Hamann, 2003). There are several 
studies about extracts from green, brown and red marine seaweeds as promising antibacterial 
agents against Vibrio parahaemolyticus which causes outbreak infections of vibriosis in fish and 
shellfish, as well as affecting human health causing gastroenteritis and food poisoning (Habbu et 
al., 2016; Cunha & Grenha, 2016). 
The novel compound Isopropoxymethyl benzylis derived, from marine red alga has promising 
potential in managing blood sugars (Simmons et al., 2005). Ascophyllum nodosum a brown 
seaweed species from the northeast coastal region of United States, contains phenolic compounds 
with antioxidant effects. The brown alga Pachydicton coriaceum produces the anti-microbial 
compound Pachydictol A which is active against S. aureus. Also, many marine seaweeds and algae 
produce alkaloid and polyketide neurotoxins including saxitoxin and brevetoxins (Gammone et 
al., 2014). Marine polysaccharides of red and brown seaweeds such as fucan, agar, carrageenan 
and alginate have many biological functions as antiviral, anticoagulant, anti-proliferative and 
antithrombotic agents. Pigments from red and blue-green algae are used as nutraceutical agents 
and in food colouring (Cavallo et al., 2013; Cunha & Grenha, 2016). 
 
1.6.3 Marine microorganisms 
 
The field of microbial marine products is considered a young science. It only started in the 1960s 
and it was not until the 1980s where its applications were recognized in clinical medicine, drug 
discovery and biotechnology. Marine microorganisms are genetically diverse and are famous for 
their production of biologically active secondary metabolites (Figure 1.5) to protect them against 
predators and in stressful environmental conditions such as biofilm formation. Marine microbial 
metabolites include polyphenols, peptides and phlorotannins (Prasad et al., 2014; Choi et al., 
2015). 
Several marine bacteria are known for their slow growth in their natural habitat which makes 
optimum incubation time an important factor for their cultivation in laboratory settings (Wu et al., 
2015; Saleem & Iqbal, 2015). Researchers have discovered a wide range of marine metabolites 
which have been successfully developed by both the biotechnology sector and the pharmaceutical 
industry. Marine bacterial products applications include, bioremediation, food industry, bio-fuel 
production, anti-fouling, cosmetics, anti-cancer drugs and antibiotics (Wietz et al., 2013; Xiong et 
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al., 2013; Gerwick & Fenner, 2013). Marine Pseudomonas species are famous for their production 
of clinically important secondary metabolites. The first antibiotic derived from marine bacteria 
was 2-(3', 5’- dibromo-2'-hydroxyphenyl)-3,4,5-tribromopyrrole from Pseudomonas bromoutilis. 
The antibiotic showed potent activity towards Gram-positive bacteria. A heat stable antimicrobial 
compound from the culture supernatant of P. aeruginosa PG-01 isolated from the Persian Gulf 
showed potent activity against pathogenic Gram-positive bacteria including MRSA (Manivasagan 
et al., 2013; Darabpour et al., 2010). Microbial marine secondary metabolites of importance 
include, macrolide antibiotics, glycopeptides, anticancer agents, enzymes and pigments (Suleria et 
al., 2015; Egan et al., 2008). The full genome sequence of the marine actinomycete Salinispora 
tropica revealed 19 secondary metabolic biosynthesis gene clusters encoding different natural 
metabolites such as; terpenoids and the anticancer agent (Salinosporamide A). The bacterium also 
produces phylogenetically distinct polyketide synthases and encompasses diverse polyketide 
biosynthetic pathways, including type I polyketide synthases, type II and type III polyketide 
synthases (Gulder & Moore, 2009; Udwary et al., 2007). 
Marine Bacillus sp. such as B. marinus and B. amyloliquefaciens SH-B10 produce potent 
antibacterial and antifungal activity against S. aureus and plant associated fungal pathogens (Abad 
et al., 2011; Biswas et al., 2016). Compounds produced by marine Myxobacteria are active against 
cancer cell lines and Gram-negative pathogens (Peláez, 2006). Some species of marine 
Pseudoalteromonas produce low and high molecular weight compounds that are active against P. 
aeruginosa, methicillin-resistant S. aureus, B. subtilis, E. coli and Enterococcus species. The 
marine bacterial strain Marinomonas mediterranea produces antibacterial activity against resistant 
nosocomial bacterial strains including, Pseudomonas sp. and S. aureus (Dufourcq et al., 2013; 
Egan et al., 2008). Organic extracts of marine bacterial cultures isolated from marine sediments 
have a broad spectrum of anti-bacterial, as well as antifungal activity and identification of these 
inhibitory compounds has led to the discovery of novel marine bacterial alkaloids (Wu et al., 
2015). Many marine bacterial species produce novel carotenoid pigments with antioxidant 
activities and medicinal properties against cardiovascular diseases (Blunt et al., 2013).  
Heterotrophic cold-loving marine bacteria are important due to their production of enzymes like 
lipase, urease, gelatinase and DNase (Manivasagan et al., 2013). Marine bacteria from deep sea 
hydrothermal vents produce heat stable and acid resistant α-amylase enzymes with promising 
biotechnological potential (Cragg & Newman, 2013). Other examples of marine derived bacterial 
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enzymes include agarase, carrageenase and proteases isolated from Colwellia and Marinomonas 
species as well as DNA polymerases and DNA ligases from Thermococcus and Pyrococcus 
(Imhoff et al., 2011). Bacteria isolated from the South China Sea produce novel alkaline protease 
enzymes with thermal and chemical stability and high activity towards a variety of salt 
concentrations and organic solvents with potential applications in the detergent and food industry 
as well as in the treatment of wastewater (Shindo & Misawa, 2014; Gammone et al., 2014).  
Marine fungal species are still largely underexplored, approximately 700 novel compounds were 
discovered to date with some exhibiting bioactive properties in particular against Gram-positive 
bacteria (Navarri et al., 2016; Debbab et al., 2010). Examples of marine fungal species include, 
Penicillium, Aspergillus and Fusarium (Habbu et al., 2016) and are famous for their production of 
antibiotics, polysaccharides, polyketides, alkaloids and antioxidants (Figure 1.4) (Rateb & Ebel, 
2011; Debbab et al., 2010). Marine Fungal secondary metabolites have anti-proliferative activity 
and can inhibit methicillin-resistant S. aureus (Müllera & Wink, 2014; Xiong et al., 2013). 
 
 
 
Figure 1.4: Examples of marine-derived fungal compounds (Rateb & Ebel, 2011) 
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Figure 1.5: Diversity of marine microbial metabolites and their various applications (Bhatnagar & Kim, 2010). 
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1.7 The genus Serratia  
 
1.7.1 Classification 
  
Serratia species of the family Enterobacteriaceae are rod shaped opportunistic Gram-negative 
bacteria of the c subclass of Proteobacteria and are motile, psychrophilic and facultatively 
anaerobic (Grimont & Grimont, 1978; Akele et al., 2015). They are named after the Italian 
physicist Serafino Serrati. They are ubiquitous; inhibit a variety of different environmental niches 
such as; water, soil, plants as well as insects and animals with some associated with food spoilage. 
Some examples of Serratia include, S. fonticola, S. plymuthica, S. marcescens and S. grimesii 
(Kamble & Hiwarale, 2012; Williamson et al., 2005; Weise et al., 2014). 
In laboratory settings, Serratia species can grow on solid media at temperatures ranging from 20°C 
to 37°C while, in liquid media from 5 °C to 40 °C with optimum pH values of 5- 9. Serratia grow 
in many complex growth media, these include LB, PDA and NA (Stock et al., 2003; Houdt et al., 
2007; Houdt et al., 2014; Stancu, 2016). The production of antimicrobial compounds by Serratia 
is carbon source dependent and highly induced in the presence of nutrients like organic acids and 
sugars and temperature-regulated with enhanced production at lower temperatures since seasonal 
variations are a major factor in influencing bacterial metabolic activity (Matilla et al., 2016a; 
Masschelein et al., 2015b; Adam et al., 2016). 
 Some strains of Serratia, in particular S. marcescens are human pathogens and the causative 
agents of contamination in hospital medical devices. S. marcescens associated with nosocomial 
infections cause pneumonia, septicemia, meningitis, endocarditis and urinary tract infections 
(Vleesschauwer & Hofte, 2007; Ashelford et al., 2002; Bonnin et al., 2017; Uğras et al., 2014; 
Ersoz et al.,2014). 
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1.7.2 The red pigment prodigiosin 
 
For many years now, natural pigments from microbial sources have been studied for their various 
biological activities. These include anti-oxidants, antifungal and immuno-suppressive properties. 
Prodigiosin is a red non-diffusible, water-insoluble pigment bound to the bacterial cell envelope 
of some strains of Serratia such as S. plymuthica, S. marcescens and S. rubideae. However, the 
pigment is soluble in organic solvents such as methanol (Elkenawy et al., 2017; Jafarzade et al., 
2013; Darshan & Manonmani, 2015; Grimont & Grimont, 1978).  
Prodigiosin is an alkaloid secondary metabolite with colours ranging from dark red to pale pink 
notably on nutrient agar. The majority of reported S. marcescens isolates are of clinical origins and 
appear non-pigmented in comparison to environmental strains. It is strongly believed that it is 
temperature related since the optimal temperature for the production of prodigiosin is 28°C (Weise 
et al., 2014; Su et al., 2016; Faraag et al., 2017).  The biosynthesis of prodigiosin is controlled by 
numerous environmental and physiochemical factors including temperature, oxygen and pH with 
maximum production yields achieved in the absence of light. The availability of nutrients in media 
composition like carbon, nitrogen, inorganic phosphate and salts can influence the production of 
prodigiosin and a number of selective broth media are used for the production of the pigment. 
These include marine broth, nutrient broth, peptone glycerol broth and sesame seed broth (Darshan 
& Manonmani, 2015; Vleesschauwer & Hofte; 2007). 
The structure of prodigiosin includes three pyrrole rings with two linked together and the third ring 
attached to a methene forming a pyrrolopyrrole-ethene linkage (Moons et al., 2006; Ibrahim et al., 
2014). The production of prodigiosin is controlled by a cluster of operonic genes called pigA-O 
(Ruiz et al., 2010; Elkenawy et al., 2017). Prodigiosin appears in the later stages of bacterial 
growth with no obvious physiological function. Nevertheless, studies speculated on the true 
biological functions of prodigiosin. These include, acting as an overflow for metabolic cellular 
waste products in the producing strains, contributing to surface adherence and enhancing bacterial 
dispersal while other studies claim that it might act as a sink for excess proline such as in 
Streptomyces (Harris et al., 2004; Fineran et al., 2005b). 
The pigment displays anti-malarial, more general anti-protozoal activities, anti-fungal activities, 
and a promising potential as an anti-cancer agent due to its potent apoptotic activity in T and B 
lymphocytes but low cytotoxicity towards normal cells (Faraag et al., 2017; Bentley, 1999; Slater 
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et al., 2003). Prodigiosin shows bacteriostatic effects with anti-bacterial activity against numerous 
pathogenic strains. These include, E. coli, E. faecalis, S. pyogenes and Acinetobacter species 
(Lapenda et al.,2015; Wang et al., 2016). Prodigiosin extracts purified from S. marcescens IBRL 
USM 84, Serratia marcescens B2 and S. marcescens B10 VKM are active against S. aureus, P. 
aeruginosa, B. subtilis, B. cereus, salmonella, Shigella, C. albicans, C. utilis, Cryptococcus as well 
as algal blooms (Kimyon et al., 2016; Thomson et al., 2000; Pore et al., 2016). 
 
1.7.3 The commercial and biotechnological applications of Serratia  
 
Serratia produce commercially important compounds and enzymes such as lipases, serralysin, 
chitinases, nucleases, protease, haemolysin and amylases. Some strains of Serratia marcescens 
secrete chitinase B which is characterized by high thermal stability. It is strongly believed that 
enzymatic production in Serratia is due to their ability to inhabit various environmental habitats 
(Akele et al., 2015; Abdou, 2003; Harris et al., 2004; Williamson et al., 2005). 
There is a great interest in the role of Serratia as cost-effective and environmental-friendly 
bioremediation agents. S. marcescens B742 synthesizes protease and chitosanase and hydrolyzes 
the proteinsin SSP protein produced by shrimp shell wastes into water-soluble protein hydrolysates 
(Gaeseidnes et al., 2003; Zhang et al., 2014). 
Serratia isolated from soil and water samples encompass unique enzymatic activity and can 
degrade carboxylic acids (nitriles). Serratia sp. ISTVKR1 biodegradable activity include various 
chemical compounds and contaminants including organophosphorus pesticides, methyl parathion 
and p-nitrophenol (Gupta and Thakur, 2015; Alag et al., 2015). Serratia strains isolated from 
petroleum-contaminated sites in Norway coastline produce hydrocarbon-degrading activity with 
great biotechnological potential in the remediation of oil and petroleum spills. A novel non-
pigmented strain of Serratia isolated from a river in India can hydrolyse urea to ammonia 
(Ashelford et al., 2002; Frankowski et al., 2001).  
There are numerous studies regarding the important role of Serratia as bio-control agents in 
agricultural crops management including strawberry, cauliflower and olives. S. plymuthica A30 
shows potent activity against the bacterium pathogen Dickeya solani that cause blackleg and soft 
rot in potato (Petersen & Tisa, 2013; Matilla & Salmond, 2014; Czajkowski & Wolf, 2012). 
Serratia strains used as environmental bio-control agents include, S. proteamaculans and Serratia 
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sp. ANU101 which produce various compounds including the antifungals haterumalides which 
were the first polyketides to be discovered in Serratia (Adam et al., 2016; Stock et al., 2003; Lim 
et al., 2015). The novel strain Serratia marcescens B4A produces potent antifungal compounds 
and inhibit the growth of insects and plant pathogens such as Rhizoctonia solani and Alternaria 
raphanin. The following strains of Serratia, Serratia marcescens, Serratia plymuthica, Serratia 
sp. SY5, Serratia fonticola AU-P3 and Serratia fonticola DSM 4576T are plant growth promoting 
bacteria. They enhance crop yields and ecological balance in the agroecosystem by facilitating the 
uptake of nutrients from the environment. They also produce secondary metabolites such as 
siderophores and phytohormone and protect the plants against pathogenic infections (Zarei et al., 
2011; Matilla et al., 2016b; Lim et al., 2015). 
Some strains of Serratia including, Serratia plymuthica HRO-C48 produce the halogenated 
secondary metabolite pyrrolnitrin which is a promising agricultural fungicide (Cleto et al., 2014; 
Liu et al., 2007; Bhadra et al., 2005). Serratia nematodiphila DSM 21420T is a biological pest 
control agent and produce potent insecticidal Sep proteins (SepA, SepB, SepC). A full genome 
sequence of the strain showed gene clusters encoding enzymes contributing to antimicrobial 
production (Kwak et al., 2015). The following strains of Serratia including, S. plymuthica 4Rx13, 
S. marcescens Db11, S. odorifera DSM 4582 and S. plymuthica PRI-2C produce volatile organic 
compounds VOCs including dimethyl trisulfide, sodorifen and methanethioland terpenoids 
(Popova et al., 2014; Su et al., 2016; Neupane et al., 2012). These compounds have cytotoxic 
broad bacteriostatic inhibitory activity against various pathogenic bacteria and fungi, fruit flies and 
nematodes (Dang et al., 2015; Schmidt et al., 2017). 
 
1.7.4 Serratia a novel source of antimicrobial compounds  
 
Serratia produce novel secondary metabolites with potent antibacterial (Table 1.1), anti-fungal as 
well as anticancer activities (Matilla et al., 2016a). Some strains of Serratia have a highly species-
specific secretion-system (type VI) also known as T6SS which enables the production of broad-
spectrum bioactive compounds. This system facilitates the production of antibacterial 
toxins and self-protecting bacteriophage contained proteins that contribute to virulence against 
competitors and even related Serratia strains (Petersen & Tisa, 2013; Hellberg et al., 2015; Fritsch 
et al., 2013). 
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The production of bioactive secondary metabolites in Serratia is due to quorum sensing (QS) 
(Chernin et al., 2011; Su et al., 2016). QS regulates gene expression in many Gram-negative 
bacteria in response to environmental selective pressure like the depletion of nutrients and 
influences population density by the production of N-Acyl homoserine lactone (AHL) molecules 
(Liu et al., 2011; Thomson et al., 2000; Wencewicz, 2016). AHL are intercellular auto-inducer 
diffusible signaling molecules biosynthesized by the enzyme LuxI and regulates the production of 
antimicrobials, antibiotics, enzymes and plant growth promoting compounds as well as 
contributing to motility, sporulation, virulence and biofilm formation (Weise et al., 2014; Sanchez 
et al., 2010b). There are various studies regarding the antimicrobial metabolites of Serratia 
(Table1.1). The culture supernatant of Serratia marcescens 2170 have strong cytotoxic activity 
against cancer cell lines (Coulthurst et al., 2004). Also, Serratia sp. strain American Type Culture 
Collection 39006 produces the broad spectrum β-lactam antibiotic Carbapenem. S. marcescens 
274 and Serratia 39006 secrete haemolysin, prodigiosin (Montaner et al., 2000; Fineran et al., 
2005a). 
Some strains of S. marcescens such, as S. marcescens strain NSK-1and S. marcescens IBBPo15 
produce the lipopeptide compounds, serrawettins synthesized by polyketide synthases. 
Serrawettins are broad spectrum antibacterial bio-surfactants and potent anticancer agents against 
T-cell leukemia and Burkittis lymphoma (Su et al., 2016; Penesyan, 2010). 
Recent research regarding S. plymuthica A153 and S. marcescens MSU97 revealed the production 
of the antifungal compound antioomycete, the anticancer agent haterumalide and the antibiotic 
andrimid. The latter inhibits the growth of Salmonella enteritidis, Yersinia enterolitica, Vibrio 
harveyi and Enterococcus (Matilla et al., 2016b; Uğras et al., 2014; Martinez et al., 2015).  
S. grimesii and S. proteamaculans produce anti-cancer metabolites active against human larynx 
carcinoma (Malheiros et al., 2015; Matilla et al., 2016a). Some Serratia produce the exoenzymes 
oocydin A and bacteriocins (Williamson et al., 2006; Sanchez et al., 2010 b). S. marcescens Db10 
secretes the antibacterial toxins Ssp1 and Ssp2 and produces self-resistance proteins as a protection 
mechanism from its own toxins (Cleto et al., 2014; Matilla & Salmond, 2014). Strains of Serratia 
such as S. plymuthica, Serratia sp. strain V4 and S. plymuthica RVH1 produce zeamine antibiotics 
which have broad spectrum bactericidal activity against multidrug resistant bacteria and yeast. 
Zeamines cause membrane permeabilization through hydrophobic interactions with phospholipid 
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layers and have cyto-toxic activities against human cancer cell lines (Ovadis et al., 2004; 
Masschelein et al., 2015a; Masschelein et al., 2013). 
 
Table 1.1: Examples of Serratia antimicrobial metabolites 
 
Strain Metabolite(s) and antimicrobial 
activity 
Reference 
S.marcescens 
IBBPo15  
Serrawettins: Broad spectrum 
antibacterial compounds 
(Penesyan, 2010) 
S. plymuthica A153 Haterumalide: Inhibit bacterial 
protein biosynthesis 
(Matilla et al., 2016b) 
Serratia sp. strain 
American Type 
Culture Collection 
39006 
Carbapenem: Inhibit bacterial cell 
wall synthesis 
(Montaner et al., 2000) 
S. plymuthica 
RVH1 
Zeamines: Affect the integrity of 
bacterial cell membrane. 
(Ovadis et al., 2004) 
Most S. marcescens 
strains 
Prodigiosin: Bacteriostatic anti-
bacterial activity, affect the bacterial 
cell membrane and decrease the 
cells respiration activity. 
(Faraag et al., 2017; 
Bentley, 1999; Wang 
et al., 2016; Thomson 
et al., 2000; Pore et 
al., 2016; Danevcic et 
al., 2016) 
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1.7.5 Antimicrobial polyketides 
 
The discovery of polyketides was by James Collie in 1883 but it was not until the 1950s that the 
field of polyketide research was established by Arthur Birch after his work on the aromatic 
polyketide (6-methylsalicylic acid) from Penicillium patulum (Snyder et al., 2003; Tang et al., 
2004; Gallo et al., 2013). 
Polyketides are structurally diverse natural secondary metabolites. They are synthesized by a 
family of multi-modular enzymes known as polyketide synthases (PKSs) from the oligomerization 
of carboxylic acids (Korman et al., 2010; Donadio et al., 2007; Kwan & Schulz, 2011). PKSs 
consist of separate enzymatic domains. These include, a ketosynthase (KS), an acyl carrier protein 
(ACP) and an acyltransferase (AT) (Gerc et al., 2012; Bedford et al., 1996). These domains are 
responsible for the incorporation of a specific building block or intermediate product leading to 
the formation of the final product in an ‘assembly-line’ fashion (Mcdaniel et al., 1999; Wagner et 
al., 2016; Sundaram et al., 2015).   
The unique biodiversity of polyketides is largely due to the order of the modules which determines 
chemical pathways and the structure of the final product. The biosynthesized polyketides can go 
through a secondary modification step in the post-PKS process where their chemical structure is 
further oxidized or methylated by O-methyl transferase (Zhang et al., 2009; Wiesmann et al., 1995; 
Cheng et al., 2009; Callahan et al., 2009). Horizontal gene transfer also contributes to the 
biodiversity of polyketides through exchanged or altered modules leading to alternate tailoring 
enzymes and the production of new polyketides (Hojo et al., 2015; Bachmann, 2016; Matilla et 
al., 2015). 
For many years, there has been a great interest in bacterial PKS genes and the fascinating 
metabolites they encode (Dutta et al., 2014; Nair et al., 2012). PKSs genes are widely distributed 
within bacterial communities and organized in gene clusters within bacterial genomes but not 
necessarily as single operons. PKSs derived secondary metabolites represent a vast collection of 
bioactive products with some studies emphasizing their importance in the survival and 
pathogenicity of the producer strains (Shen, 2003; Staunton & Weissman, 2001). 
PKS genes have been found in many strains of Serratia in particular S. plymuthica, S. marcescens 
and S. odorifera. These genes are responsible for the production of novel compounds with 
bioactive functional and structural diversity and applications in medicine and clinical practices. 
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These include anti-bacterial, anticancer, anti-fungal, anti-parasitic and immunosuppressive 
properties (Awodi et al., 2017; Chan et al., 2009; Snyder et al., 2003). The pharmacological 
importance of these compounds and their analogues exceed $10 billion per year. These include, 
tetracyclines, rapamycin, lovastatin, streptomycin and amphotericin (Kwan & Schulz, 2011; 
Kodama et al., 2005). 
Bacterial PKSs can be categorized into three different types and share the same functionality but 
differ in structure. Type I PKSs are multifunctional enzymes organized into modules, located in a 
single protein and regulate the synthesis of different non-similar polyketide products and account 
for approximately one-third of clinical drugs in the pharmaceutical market. Examples include, 
erythromycin and epothilone (Menzella et al., 2010; Shen, 2003; Nair et al., 2012). Type II PKSs 
are composed of complex single module proteins but with separate enzymatic activities and 
synthesize aromatic polycyclic polyketides like tetracenomycin and doxorubicin (Eichholz et al., 
2012; Sanchez et al., 2010b). Type III PKSs consist of a single active site enzyme that controls the 
biosynthesis of the final product like the aromatic polyketides flavolin and tetracycline (Neupane 
et al., 2012; Tang et al., 2004). 
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1.8 Aims  
 
The rise of antibiotic resistance is a serious health problem affecting many people around the world 
and the search of effective antimicrobials is urgently needed to combat this resistance.  
Bacterial derived bioactive metabolites have been around for billions of years in environmental 
habitats as natural means of defense and the majority of clinical drugs currently used are 
derivatives of these metabolites.  
The environment, including the marine environment encompass enormous biodiversity with 
remarkable natural compounds with great capabilities for drug discovery and the synthesis of 
antimicrobial agents. Marine bacteria produce natural metabolites with unique biological 
properties and understanding the biochemical nature of these compounds is the key for future 
development of new drugs and antibiotics.  
Serratia species synthesize a diverse array of secondary metabolites, many of which represent a 
promising renewable and valuable resource for pharmaceutical industry and research. 
 The aim of this project was to characterize the secreted antibacterial activity of an environmental 
isolate of S. plymuthica and determine whether there was more than one compound responsible 
for this activity.  
 
❖ The specific objectives of this study were:  
 
1- Optimization of secreted antibacterial activity by investigating the influence of different 
incubation periods, media composition and culture vessels on the production and amount of 
secreted antibacterial compound(s) by the environmental isolate S. plymuthica. 
2- Characterization of secreted antibacterial activity by investigating its stability towards storage 
temperatures, Proteinase K, pH and TWEEN. 
3- Estimating the molecular weight of the secreted antibacterial compound(s).  
4- Investigating the spectrum of secreted antibacterial activity and if its bactericidal or 
bacteriostatic  
5-Genetic analysis of S. plymuthica using (Transposon mutagenesis) and cloning the genomic 
region(s) that code for antimicrobial activity. 
6-Isolation and purification of the secreted antimicrobial compound(s). 
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7- Structural characterization of the secreted antibacterial compound(s) via NMR and COSY 
spectrometry. 
 
 Finally, the agents of the antibacterial activity were evaluated for potential development as 
commercial antimicrobial compounds.  
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CHAPTER 2: MATERIALS AND METHODS 
 
2.1 General methods 
 
2.1.1 Materials  
 
All chemicals, culture media, reagents, enzymes and other materials used in this study were 
purchased from Sigma-Aldrich (UK) and OXOID, MELFORD, Fisher Scientific (UK), 
FORMEDIUM and Helena Bio Sciences unless otherwise stated in the text. Manufacturers’ 
instructions were applied on storing and handling of the materials. Media, solutions, tips and 
glassware were autoclaved at 121oC for 15 mins. 
 
2.1.2 Centrifugation 
 
Centrifugations were run according to manufacturers’ instructions and at an appropriate speed and 
temperature using an Eppendorf™ Minispin bench top centrifuge for small samples (500µl-2 ml) 
while larger ones measuring up to 50 ml were centrifuged using a Beckman coulter allegra X-12R 
bench top centrifuge. 
 
2.1.3 Growth media and cultivation conditions 
 
For the purpose of this study, microbial strains were cultured on nutrient agar (NA) plates (28g/L) 
and in nutrient broth BN (25 g/L) for 18h-24h. E. coli strains were grown on Luria-Bertani LB 
agar plates (Composition per 1L: LB broth 25g and 14g Agar) and in LB broth (25g/L) and 
incubated at 37°C for 24h. Fungal and yeast strains were grown on YPD agar plates; (Composition 
per 1 L: 10g yeast extract, 20g peptone, 20g glucose anhydrous and 20g agar) and incubated at 25 
°C for 2 days. Additional media used in this study include Brain heart infusion broth BHI (37g/L) 
and de Man, Rogosa and Sharpe MRS broth (52g /L). Antibiotics [kanamycin (50μg/μl) and 
ampicillin (50μg/μl)] were added as needed to growth media after cooling to (~55oC) after 
autoclaving.  Incubations were performed aerobically on a shaking plate/shaking water at 
appropriate temperatures and at a speed of (120 rpm). 
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2.2 Microbial strains and plasmids 
 
A variety of microorganisms including bacteria, yeast and fungi were used in this study as shown 
in Table 2.1. 
 
2.2.1 Wild type strain 
 
In 2009, the environmental strain S. plymuthica was isolated by Narges Khalaf from the surface of 
the seaweed Ascophyllum nodosum from Hawcraig point at Aberdour beach, Scotland (Figure 2.1). 
 
 
 
Figure 2.1: Sample collection site at Hawcraig point, Aberdour beach, Scotland 
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Table 2.1 Microbial strains and plasmids used in this study 
 
Strain or plasmid Characteristics Growth 
conditions 
Source 
Serratia plymuthica 
(P) 
Wild-type 
(Environmental isolate) 
 
NA, NB 
(RT/18h) 
D. Jamieson1 
Staphylococcus 
aureus  
(ATCC 25923) 
Indicator strain NA, NB 
(37oC/24h) 
P. Cyphus2 
Bacillus cereus 
variant of mycoides 
(F) 
Indicator strain 
(Environmental isolate) 
NA, NB 
(30oC/24h) 
D. Jamieson 
Bacillus cereus  
(ATCC 11778) 
Indicator strain NA, NB 
(30oC/24h) 
P. Cyphus 
Bacillus subtilis 
(ATCC 6633) 
Indicator strain 
 
NA, NB 
(30oC/24h) 
P. Cyphus 
Pseudomonas 
aeruginosa 
Indicator strain 
 
NA, NB 
(37oC/24h) 
S. IIincheta3 
Salmonella enterica 
variant of   
Enteritidis (S) 
(ATCC 13876) 
Indicator strain 
 
NA, NB 
(35oC/24h) 
S. IIincheta 
Klebsiella 
pneumoniae  
(ATCC 13883) 
Indicator strain 
 
NA, NB 
(37oC/24h) 
S. IIincheta 
Enterococcus 
faecalis  
(ATCC 29212) 
Indicator strain 
 
NA, NB 
(37oC/24h) 
S. IIincheta 
Serratia marcescens Indicator strain 
 
NA, NB 
(30oC/24h) 
S. IIincheta 
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Table 2.1 (continued) 
 
Strain or plasmid Characteristics Growth 
conditions 
Source 
Saccharomyces 
cerevisiae 
(ATCC 4098) 
Indicator strain 
 
YPD, YPD broth 
(37oC/24h) 
S. IIincheta 
Candida tropicalis 
LAMB C.tr  
(Neogen laboratories 
collection) 
Indicator strain 
 
YPD, YPD broth 
(30oC/24h) 
S. IIincheta 
Candida krusei 
LAMB Asp.C76  
(Neogen laboratories 
collection) 
Indicator strain 
 
YPD, YPD broth 
(24oC/24h) 
S. IIincheta 
Saccharomyces 
diastaticus  
Y361 
Indicator strain 
 
YPD, YPD broth 
(37oC/24h) 
S. IIincheta 
Escherichia coli  
(ATTC 25922) 
Indicator strain 
 
LB, LB broth 
(37oC/24h) 
S. IIincheta 
E. coli (BW2020767) Donor strain 
Tn5-RL27 (KmR-
oriR6K) 
LB, LB broth +50 
μg/ml Km 
(37oC/24h) 
(Larsen et al., 
2002) 
E. coli S17-1 λpir Recipient of 
recombinant plasmids 
LB, LB broth 
(37oC/24h) 
(Simon et 
al.,1983) 
E. coli EC100D™ pir-
116 
Recipient of 
recombinant plasmids 
LB, LB broth 
(37oC/24h) 
TransforMax™ 
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Table 2.1 (continued) 
 
Strain or plasmid Characteristics Growth 
conditions 
Source 
E. coli EC100D™ pir+ Recipient of 
recombinant plasmids 
LB, LB broth 
(37oC/24h) 
TransforMax™ 
P1-P8 A self-ligated 2000 bp 
EcoRІ fragment of S. 
plymuthica 
chromosomal DNA with 
Tn5-RL27 (KmR-oriR6 
K) 
LB, LB broth +50 
μg/ml Km 
(37oC/24h) 
This study 
WP1-WP5 A self-ligated 5500 bp 
EcoRІ fragment of S. 
plymuthica 
chromosomal DNA with 
Tn5-RL27 (KmR-oriR6 
K) 
LB, LB broth +50 
μg/ml Km 
(37oC/24h) 
This study 
1-D. Jamieson, School of Energy, Geoscience, Infrastructure and Society, Heriot Watt University, Edinburgh, UK 
2-P. Cyphus, School of Energy, Geoscience, Infrastructure and Society, Heriot Watt University, Edinburgh, UK 
3-S. IIincheta, School of Energy, Geoscience, Infrastructure and Society, Heriot Watt University, Edinburgh, UK 
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2.3 Preservation and maintenance of bacterial strains and plasmids 
 
The preservation of microbial strains/plasmids was performed as follows: stock cultures: single 
colonies were picked from the designated culture plate using a sterile loop and transferred to falcon 
tubes (50 ml) containing 5 ml of the appropriate liquid medium before incubation for 24h with 
shaking (120 rpm). The bacterial culture (500 µl) was mixed with an equal volume of 50% (v/v) 
glycerol. The samples were labeled with a designated name and date and stored at -80oC until 
needed. Working cultures: kept on appropriate agar plates/ broth at 4 °C. 
 
2.4 Preparation of cell-free culture supernatants (CFCS) 
 
In this study, the preparation of the CFCS was done as follows: the environmental strain (S. 
plymuthica) was grown in 500 ml flasks containing 100 ml of NB broth at 25oC with shaking (120 
rpm) for 48h-72h.The bacterial cultures were poured into 50 ml centrifuge tubes and centrifuged 
at 3000x g for 15mins. The supernatant was collected carefully without disturbing the pellet and 
placed into new centrifuge tubes. The culture supernatants were sterilized by two methods; heat 
treatment by placing the samples into a hot water bath (Grant SUB 14) at 70oC for 10mins or by 
flirtation using a (0.2 µm) cellulose acetate filter. 
 
2.5 Detection of antibacterial activity 
 
The presence of antibacterial activity was assessed by performing a spot agar assay against an 
appropriate indicator strain as follows: 100 µl of an overnight culture of an appropriate indicator 
strain was spread onto NA plates using sterile glass beads. The glass beads were removed, and the 
plates were left to dry at RT for (15-20mins). The desired samples to be tested for antibacterial 
production were spotted onto the center of the plates (20 μl) and incubated appropriately. A visible 
clear zone represents an area of growth inhibition and its size was recorded as illustrated in the 
following figure: 
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Figure 2.2: An illustration of a spot agar assay. A; bacterial lawn of an indicator strain. B; zone of inhibition is recorded 
by measuring the diameter of the clear area. 
 
 
2.6 The influence of incubation period on the production of antibacterial activity 
 
The influence of incubation period on the production of antibacterial activity was tested as follows; 
Single colonies of a fresh plate of S. plymuthica were inoculated in 50 ml centrifuge tubes with 5 
ml NB broth and incubated for the following time periods: 24, 48, 72, 96 and 120h. The samples 
were incubated at 25oC with shaking (120 rpm). Centrifugation was done at 3000x g for 15mins 
and the supernatant was collected and placed into new centrifuge tubes. The samples were placed 
into a water bath at (70oC/10mins), then left to cool at RT for 15mins before being ready for 
analysis. 
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2.7 The influence of growth conditions on antibacterial production 
 
2.7.1 96 well plates 
 
The influence of growth conditions (culture vessels) on antibacterial production was tested as 
follows: Single colonies from a fresh plate of S. plymuthica were picked out using a sterile loop 
and individually inoculated into each well of a 96 well- plate (Figure 2.3). Each well contained 
300 µl of M.R.S broth media with few wells left cell free as negative controls. The plate was sealed 
with an adhesive plate semi-permeable membrane and incubated for 72h on a rotary shaker (120 
rpm) at 25oC. The plate was placed in a hot water bath (70oC/30mins) in order to eliminate S. 
plymuthica cells. The plate was left to cool at RT for 15mins before being ready for analysis. 
 
 
 
Figure 2.3: Demonstration of a 96 well- plate used to investigate the influence of growth conditions on the production 
of secreted antibacterial activity. The antibacterial producing strain (S. plymuthica) was cultivated in wells containing 
300 µl of M.R.S broth media and incubated at 25oC on a rotary shaker (120 rpm) for 72h. 
 
 
A well 
containing 
bacterial 
culture of S. 
plymuthica   
 
A negative 
control well 
with 300 µl 
of M.R.S 
broth media 
only  
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2.7.2 Centrifuge tubes (50 ml) 
 
The antimicrobial producing strain S. plymuthica (3 colonies) was cultivated in (Greiner centrifuge 
tubes, 50 ml; conical (V) bottom) containing 5 ml M.R.S broth media and incubated at 25oC with 
shaking (120 rpm) for 72h. The samples were spun using a bench top centrifuge at 3000x g for 
15mins.The culture supernatant was collected and placed into new falcon tubes. The samples were 
placed in a hot water bath (70oC/10mins) and left to cool at RT for 15mins before being ready for 
analysis. 
 
2.7.3 Flasks (250 ml) 
 
The antibacterial producing strain (S. plymuthica (5 colonies) was cultivated in 250 ml flask 
containing 20 ml of M.R.S broth media (Figure 2.4) and incubated at 25oC with shaking (120 rpm) 
for 72h.   Bacterial culture samples were placed into centrifuge tubes. Centrifugation was done at 
3000xg for 15mins. The culture supernatant was placed into new centrifuge tubes and placed in a 
hot water bath for (70oC/10mins) and left to cool at RT for 15mins before being ready for analysis. 
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Figure 2.4: Demonstration of 250 ml flasks used to investigate the influence of growth conditions on the production 
of secreted antibacterial activity. The antibacterial producing strain (S. plymuthica) was inoculated in 20 ml M.R.S 
broth media and incubated at 25oC with shaking (120 rpm) for 72h. 
 
 
2.8 The influence of cultivation temperatures and media composition on antibacterial production 
 
The influence of cultivation temperatures and media composition on the production of secreted 
antibacterial activity was investigated as follows: The environmental strain S. plymuthica was 
grown in 250 ml sterilized flasks containing 20 ml of the following broth media: NB broth, LB 
broth, M.R.S broth and BHI and incubated at (16oC, RT, 30oC and 35oC) with shaking (120 rpm) 
for 72h. Bacterial culture samples were placed into centrifuge tubes and centrifugation was done 
at 3000x g for 15mins. The culture supernatant was placed into new centrifuge tubes and placed 
in a hot water bath (70oC) for 10mins. The samples were left to cool at RT for 15mins before being 
ready for analysis. 
 
 
 
 
Bacterial cultures of 
the antibacterial 
producing strain  
 
 
 
42 
 
2.9 Effect of heat-treatments on antibacterial activity  
  
The effect of heat-treatments on antibacterial activity was assessed by subjecting the culture 
supernatant of the antibacterial producing strain (S. plymuthica) to the following temperatures 
(60oC, 70oC, 80oC, 90oC, 100oC) using a water bath for 10mins; heating time did not include the 
time to attain the desired temperature. 
 
2.10 Stability of antibacterial activity  
 
2.10.1 Effect of storage temperatures on antibacterial activity  
 
 The effect of storage on the stability of the antibacterial activity was tested by placing the desired 
sample at 4oC for 7 days and recording the presence of antibacterial activity against an appropriate 
indicator strain. 
 
2.10.2 Effect of Proteinase K on antibacterial activity 
 
Enzymatic treatment was performed by incubating Thermo Scientific Proteinase K stock solution 
(20 mg/ml) with the desired sample before incubation at 37°C for 3h. The desired sample (100 µl) 
was mixed with (80 µl) of Proteinase K stock solution (20 mg/ml) and sterile distilled water (20µl) 
and incubated for 3h at 37oC.  
 
2.10.3 Effect of (TWEEN® 20) on antibacterial activity 
 
The detergent; surfactant TWEEN® 20 1% (v/v) was mixed with an equal volume of the desired 
sample and incubated in a heating block (37oC/3h). 
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2.10.4 Effect of pH on antibacterial activity 
 
The effect of acidification and alkalization on respective samples was carried out using HCl (1M) 
(HCL 48ml, distilled water 500ml) and NaOH (1M) (NaOH 20g, distilled water 500ml) to adjust 
the pH. Acidification was done by adjusting the pH of the desired sample to pH 5 using HCl and 
alkalization was done by increasing the pH of the desired sample to pH 9 using NaOH. Samples 
were incubated at 22oC for 2h with shaking (120 rpm). 
 
2.10.5 Effect of Tris buffer on antibacterial activity 
 
A Tris buffer; [Tris-HCl pH 7.0 (50 mM), NaCl (50mM), Glycerol (5%) and EDTA (2mM)] was 
added to the desired sample (10:1; Tris-buffer: sample) before incubation at 25oC for 2h with 
shaking (120 rpm). 
 
2.11 Properties of antimicrobial activity 
 
2.11.1 Estimation of the molecular weight of the antibacterial compound(s) 
  
Amicon ®Ultra-15 Centrifugal Filter Units (3,000 MWCO) and (10,000 MWCO) were used on 
respective samples according to manufacturer's instructions. 
 
2.11.2 Measuring the effect of antibacterial activity on bacterial growth 
 
Single colonies from a fresh plate of the indicator strain B. cereus were picked out using a sterile 
loop and inoculated into 50 ml centrifuge tubes with 10 ml of NB and incubated at 37ºC with 
shaking (120 rpm) for 24h. The overnight culture (100 μl) was inoculated into 10 ml of NB and 
incubated at 37oC with shaking (120 rpm) until (OD600 ~0.5). The bacterial culture was distributed 
evenly (500 μl) into centrifuge tubes followed by centrifugation at 3000xg for 10mins. The 
supernatant was discarded, and the cell pellets were re-suspended in 500 μl of sterile maximum 
recovery diluent (MRD) PH 7.0; [(Formula/L: peptone (1.0 g), NaCL (8.5g)]. Centrifugation was 
performed 3 times to thoroughly wash the cells. 
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2.11.3 Spectrum of antibacterial activity  
 
The inhibitory spectrum of respective samples was investigated against a variety of indicator 
microorganisms (Table 2.1). 
 
2.12 Transposon mutagenesis 
  
Transposon mutagenesis was performed using plate mating between S. plymuthica and E. coli 
(BW2020767) carrying plasmid pRL27.The plasmid contains a mini-Tn5 element which encodes 
resistance to kanamycin (KmR) (Larsen et al., 2002; Lorenzo et al., 1990).  
 
2.12.1 Conjugation  
  
Plasmid pRL27 was transferred to S. plymuthica as follows: single colonies from a fresh plate of 
the donor strain [E. coli (BW2020767)] were picked aseptically and inoculated in 5 ml of LB broth 
supplemented with 50μg/ml of the antibiotic Kanamycin (Km) while, the recipient strain S. 
plymuthica was inoculated in 5 ml of NB. The bacterial cultures were incubated at 37oC and 25oC 
respectively under shaking condition (120 rpm) for 24h. Then 100 μl of each bacterial culture; 
donor and recipient were added to 10 ml of LB and NB and incubated as previously mentioned 
until mid-exponential phase O.D.600 ~0.8. Then, 1 ml of the donor bacterial culture was 
concentrated via centrifugation at 3000 x g for 10mins, the supernatant was discarded and the 
pellet was washed three times with sterile water. The donor strain and the recipient strain were 
mixed at a 1:1 volume ratio (100µl:100µl) and divided into aliquots of 20 µl and spotted onto NA 
plates and incubated at RT for 24h. 
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2.12.2 Transposon selection  
   
After incubation, colonies were scraped off and re-suspended in 10 ml of sterile MRD. Serial 
dilutions were prepared (1/100, 1/1000, 1/10,000) and cells were plated (including undiluted cells) 
onto NA plates supplemented with the antibiotics: 50µg/ml Kanamycin (Km) and 50 µg/ml 
Ampicillin (Amp) so that the former selects for the Tn5-transposon while the latter eliminates E. 
coli donor cells and any contaminants. The plates were incubated at RT for 24h/48h in order to 
isolate S. plymuthica transconjugants (Figure 2.5). KmR colonies were picked out aseptically and 
sub-cultured onto NA plates+ (50µg/ml Km). 
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Figure 2.5: Transposon mutagenesis was used in this study between the wild type (S. plymuthica) and E. coli 
(BW2020767). This method includes three stages: conjugation, transposon selection and production of S. plymuthica 
transconjugants (KmRmutants). 
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2.13 Screening for mutants deficient in antibacterial activity  
 
Using a sterile loop, transconjugant colonies were picked out from designated stock plates and 
inoculated into centrifuge tubes to yield sufficient aeration. The tubes contained 1 ml of MRS broth 
without antibiotic; in the mini-Tn5, the transposase (Tnp) is located outside the inverted repeats 
which prevents further transposition and ensures the stability of Tn5 in target DNA (Dennis & 
Zylstra, 1998). Bacterial culture samples of mutant strains were incubated at 16oC under shaking 
condition (120 rpm) for 72h. Screening was done by performing a spot agar assays using the 
mutants CFCS against the indicator strains B. cereus and (F). Mutant strains which lacked 
antibacterial activity in the CFCS, eg., lack of a zone of inhibition against the indicator strain were 
isolated and subjected to further tests. 
 
2.14 DNA methods 
 
All primers used in this study were purchased from MWG Eurofinns. Primers were re-suspended 
in sterile distilled water to a final concentration of (100 pmol/μl) before being stored at -20oC. 
 
 
Table 2.2 Classification of primers used in this study 
 
Name Sequence (5′–3′) Target 
AGPT-F ATTCAACGGGAAACGTCTTG KmR gene1 
AGPT-R ACTGAATCCGGTGAGAATGG KmR gene1 
tpnRL17-1 
 
AACAAGCCAGGGATGTAACG 
 
Outward directed 
primer2 
tpnRL13-2 CAGCAACACCTTCTTCACGA Outward-directed 
primer2 
1. Callum Scott Thesis, Heriot Watt University 
2. Larsen et al., 2002 
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2.14.1 Genomic DNA Extraction 
 
Extraction of genomic DNA from bacterial strains was performed using the Thermo Scientific 
GeneJET Genomic DNA Purification Kit using the Gram-Negative Bacteria Genomic DNA 
Purification Protocol and following manufacturer’s instructions. Gel electrophoresis was 
performed to evaluate the efficiency of the method. Genomic DNA samples were stored at -20oC 
until needed. 
 
2.14.2 Concentration of DNA (Ethanol precipitation) 
 
Concentration of DNA (Genomic and plasmid) was performed using ethanol precipitation as 
follows: 1 volume of DNA was mixed with 1/10 volume of 3M Sodium Acetate (pH 5.2) and 2 
volumes of ice cold Ethanol (96% vol/vol) before placing the sample at -20oC for 1hr. The sample 
was centrifuged at 13000 rpm for 10mins and the supernatant was discarded.  
The pellet was washed with 1 ml Ethanol (70%) and the sample was centrifuged as previously 
mentioned. The supernatant was discarded, and the pellet was air-dried at RT for 1 hr. The DNA 
was re-suspended in 20 µl of 1X TE buffer [Formula/ L: 10 ml of 10mM Tris-HCl (pH 7.5), 2 ml 
of 1mM EDTA and 988 ml of sterile distilled water] and stored at -20oC until needed. 
 
2.14.3 Gel electrophoresis 
 
The quality of DNA samples was evaluated by performing agarose gel electrophoresis (Figure 
2.6). A sartorius analytical balance was used to weigh the agarose powder. The agarose gels were 
prepared by dissolving 0.28 g of agarose powder in 30 ml of 1x TAE buffer (pH 8.0); [Formula / 
L: 50 x TAE buffer: Tris base; 242.0g, Glacial acetic acid; 57.1 ml, 0.5 M EDTA pH 8.0; 100ml] 
in a microwave oven. The melted gel was left to cool at RT for 5-10 mins before adding 1 μl of 
Ethidium Bromide (EB); (Concentration 0.5 µg/ml). The melted gel was poured into a gel tray 
containing an appropriate gel comb and was left to settle for 15mins. The comb was removed 
carefully and the gel tray was submerged with 1x TAE buffer. All samples including a DNA 
marker (Thermo scientific 1 Kb ladder; marker) were mixed with Thermo Scientific 6X DNA 
Loading Dye; according to manufacturers’ instructions before being loaded into the gel wells and 
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run for 1 hr at 60 Volts. DNA fragments were visualized using BIO RAD Molecular Imager® 
ChemiDoc™ XRS+ system with image lab software. 
 
 
 
Figure 2.6:  Demonstration of gel electrophoreses. 1; loading DNA samples into the gel wells, 2; an electric current is 
applied (60V/1hr) and DNA molecules are separated according to molecular size. 
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2.15 Polymerase Chain Reaction (PCR) 
 
PCR was performed using Axygen® PCR tubes and contained the following: [DNA template 5µl, 
10X Dream Taq buffer (1.25 ml) 5µl, dNTP mix (10mM) 0.5 µl, forward Primer (10 pmol/µl) 1 
µl, reverse primer (10 pmol/µl) 1 µl, Dream Taq DNA Polymerase (5U/ µl,500U) 0.25 µl, Sterile 
deionized distilled water 37.25 µl]. PCR samples were placed in the GeneAmp® PCR System 
2700 thermal cycler (Figure 2.7) and a standard PCR cycle thermal reaction was performed as 
shown in the following table.  The PCR reaction mix was carried in a total volume of 50 µl. 
 
 
Table 2.3 Thermal conditions for PCR reaction 
 
Step Temperature Time 
Denaturation 94oC 2mins 
25 Cycles 94 oC 
53 oC 
72 oC 
30sec 
30sec 
1min 
Extension 72oC 7mins 
Hold 4oC ∞ 
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Figure 2.7: Demonstration of a PCR reaction performed in GeneAmp® PCR System 2700 thermal cycler. 
 
 
2.16 Enzymatic digestion 
 
Enzymatic digestion of DNA (Genomic DNA/plasmid DNA) was performed using the restriction 
enzymes BamHI and EcoRI. 
 
2.16.1 Enzymatic digestion using Bam HI 
 
Enzymatic digestion was performed in 1.5 ml sterilized eppendorf tubes. The reaction mix 
contained: sterilized deionized distilled water (30 μl), 10X FastDigest Buffer (5 μl), DNA sample 
(Genomic/plasmid) (10 μl) and Thermo Scientific FastDigest BamHI (5 μl). The samples were 
mixed for 30sec then incubated at 37°C for 5mins. The digestion reaction was terminated by heat 
inactivating the enzyme activity by placing samples in a hot water bath (80°C) for 5mins. DNA 
samples were left to cool at RT for 15mins before being stored at -20oC until needed. 
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2.16.2 Enzymatic digestion using EcoRI 
 
Enzymatic digestion was performed in 2 ml sterilized eppendorf tubes. The reaction mix contained 
the following: sterilized deionized distilled water (16 μl), 10X Buffer EcoRI (2 μl), DNA sample 
(Genomic/plasmid) (2 μl) and Thermo Scientific EcoRI (1 μl). The samples were mixed for 30sec 
and left to incubate at 37°C for 1hr. The digestion reaction was terminated by heat inactivation 
(20mins/65oC). DNA samples were left to cool at RT before being stored at -20oC until needed. 
 
2.16.3 Concentration of digested DNA 
 
Digested DNA samples were concentrated and purified using two methods: QIAGEN QIAXII gel 
extraction kit; (Desalting and concentrating DNA solutions protocol) and QIAquick PCR 
purification kit according to manufacturers’ instructions. 
 
2.17 DNA ligation 
 
 Ligation of DNA samples was performed by using Thermo Scientific T4 DNA Ligase (5 Weiss 
U/µL) and 10X T4 DNA Ligase Buffer and performed in 1.5 ml sterile eppendorf tubes. The 
ligation mix contained the following: digested DNA (1.5μl), sterilized deionized distilled water 
(25.5 μl). The sample was mixed gently by pipetting up and down 2-3 times before adding 10x T4 
DNA ligase buffer (2 μl) and T4 DNA Ligase (1 μl). The samples were mixed for few sec followed 
by incubation at 16oC for 24h. The ligation reaction was terminated by heat inactivation 
(65°C/10mins). All DNA samples were stored at -20oC until needed. 
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2.18 Preparation of competent cells  
 
2.18.1 Electro-competent E. coli cells 
 
Single colonies from a fresh plate of E. coli (S17-1 λpir) were picked aseptically and inoculated 
into sterile 100 ml flask containing 20 ml of LB broth and incubated at 37oC with shaking (120 
rpm) for 24h. The overnight culture (1 ml) was inoculated into sterile 500 ml flasks containing 100 
ml of pre-warmed LB broth and incubated at 37oC with shaking (120 rpm) until OD600~0.5-0.6. 
Bacterial culture samples were transferred to pre-chilled 50 ml centrifuge tubes and placed on ice 
for 5mins. Centrifugation was done at 4oC for 5mins at 3000 rpm. The supernatant was discarded, 
and 50 ml of ice cold sterilized 50% glycerol was added to the cells and spun again at 4oC and the 
supernatant was removed; (step repeated 4 times). The cells were re-suspended in 50% glycerol 
(500 µl) and divided into 100 µl aliquots and stored at -80oC until needed. 
 
2.18.2 Chemically competent E. coli cells 
 
This method was prepared according to the protocol by Sambrook et al., (1989). The bacterial 
strain E. coli (S17-1 λpir) was cultivated in 20 ml of LB broth media at 37oC with shaking (120 
rpm) for 24h. The overnight culture (1 ml) was added to 100 ml of pre-warmed LB broth and 
incubated at 37oC under shaking conditions (120 rpm) until OD600~0.5-0.6. Bacterial culture 
samples were placed on ice for 15mins. Centrifugation was done at 4oC for 10mins at 3000 rpm. 
The supernatant was discarded and 10 ml of ice cold 75mM CaCl2 was added to the cells and 
placed on ice for 20mins followed by another centrifugation step. The supernatant was discarded 
and pre-chilled transformation buffer TFB2 (4 ml); (10 mM 3-(N-morpholino) propanesulfonic 
acid (MOPS) [pH 7.0], 75 mM CaCl2, 10 mM RbCl and 15% Glycerol) was added to the cells. 
The cells were divided into 100 µl aliquots and stored at -80oC until needed. 
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2.19 Cloning transposon insertion sites 
 
2.19.1 Bacterial transformation  
 
All centrifuge tubes, pipet tips and cuvettes were pre-chilled prior to transformation experiments 
by placing them at 4oC for 24h in order to enhance transformation efficiency.   
 
2.19.2 Transformation of competent cells by heat shock method 
 
Frozen, chemically prepared, competent cells (100 μl) were thawed on ice before the addition of 
10µl of the diluted ligation mixture (1:20). The sample was incubated on ice for 30mins followed 
by a heat shock reaction at (42°C/30 sec) then returned on ice for 5mins. Pre-warmed (37oC) (1 
ml) of SOC buffer [Contents per 200 ml; Yeast extract (1 g), Peptone (4 g), Glucose (0.712 g), 
NaCl 5M (400 μl), KCl 1M (500 µl), MgCl2 1M (2 ml), MgSO4 1M (4 ml)] was added to the 
sample. The sample was incubated at 37°C under shaking conditions (120 rpm) for 1 hr and 
centrifugation was done at 13,000 rpm for 1 min. This Incubation step allows the bacteria time to 
generate antibiotic resistance proteins encoded on the plasmid backbone, so they will be able to 
grow once plated on an antibiotic containing agar plate. The supernatant was discarded, and the 
pellet was re-suspended in 100 µl of room temperature SOC buffer. The sample (50 μl) was spread 
on pre-warmed LB plates + 50 μg/ml Km using sterile glass beads followed by incubation at 37°C 
for 24h. 
 
2.19.3 Transformation of competent cells by electroporation 
 
Electro-competent cells (100 µl) were thawed on ice. The diluted ligation mixture (1:20) was added 
to the cells (2µl) and the sample was gently mixed by pipetting up and down 2-3 times. The sample 
was transferred to a pre-chilled cuvette then placed into the Electroporator chamber of Eppendorf, 
Electroporator 2510. The sample was placed into the electroporator and an electric pulse (1700V) 
was applied. Immediately after electroporation, 950 μl of room temperature LB media was added 
to the sample and gently mixed by pipetting before being transferred to a 15-ml falcon tube and 
incubated at 37°C under shaking conditions (120 rpm) for 1hr; (cell recovery step that allows the 
 
 
55 
 
expression of antibiotic resistance). The sample (100 µl) was spread onto LB agar plates+(50 μg/ml 
Kanamycin) and incubated for 24h at 37°C. 
 
2.20 Identification of transposon insertion sites 
 
2.20.1 Purification of plasmid DNA  
 
Single colonies of a fresh plate of the desired plasmid was picked aseptically and inoculated into 
50 ml centrifuge tube containing 5 ml of LB broth+ (50 μg/ml) of the antibiotic kanamycin and 
incubated for 24h under shaking conditions (120 rpm) at 37oC.  
Purification was performed using Thermo Scientific GeneJET plasmid miniprep kit as described 
by the manufacturers’ instructions. 
 
2.20.2 DNA sequencing 
 
DNA sequencing was performed using 8 strip tubes with a domed cap (Fisherbrand ™ 0.25 mL 
PCR tube strips). The sequencing reaction contained 6 μl and 1 μl of desired plasmid and primers 
respectively (Table 2.1 and 2.2). The samples were sent to Edinburgh Genomics and sequence 
results were compared with the databases in the National Center for Biotechnology Information 
(NCBI) (http://www.ncbi.nlm.nih.gov) using the query BLASTX. 
 
2.21 Concatenation of antibacterial activity 
 
2.21.1 Rotary evaporation  
 
Single colonies of the antibacterial producing strain were inoculated into 500 ml flasks containing 
100 ml of the appropriate medium broth and incubated at 25oC with shaking (120 rpm) for 48h 
/72h. The bacterial culture was distributed into 50 ml centrifuge tubes and centrifugation was 
performed at 3000x g for 15mins. The pellet was discarded and the culture supernatant was mixed 
with 100 ml of absolute ethanol and poured into the rotary evaporator (Heidolph) bulb. 
Temperature was set to 50˚C and pressure to 100 mbar (Figure 2.8). 
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Figure 2.8: Heidolph rotary evaporator used to concentrate respective samples by reducing the volume of the solutes. 
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2.21.2 Freeze-drying 
 
Single colonies of the antibacterial producing strain were inoculated aseptically into 250 ml flasks 
containing 50 ml of NB broth and incubated at 25oC with shaking (120 rpm) for 48h /72h. The 
bacterial culture was distributed into 50 ml centrifuge tubes and centrifugation was performed at 
3000x g for 15mins. The supernatant was collected and placed into new centrifuge tubes and heat-
sterilized at (70oC/10mins). After cooling for 15mins at RT, the supernatant was distributed evenly 
in shallow plates in preparation for freeze drying. The plates were placed at -20oC for 24h. Control 
sample; 50 ml of NB without bacterial culture. All samples were loaded into an Edwards Super 
Modulyo Freeze Dryer (Figure 2.9) for 48h. 
 
 
 
Figure 2.9: Edwards Super Modulyo Freeze Dryer used to concentrate respective samples. Freeze-drying is applied at 
(0.05 – 1) mbar and transforms solvents directly into vapour. 
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2.22 Purification of the antibacterial compound(s) by organic solvent extraction 
 
The concentrated culture supernatant (CCS) was mixed with an equal volume of the organic 
solvent (methanol). Controls: (positive control; the CSS without the organic solvent, negative 
control; methanol only). All samples were incubated at 25oC for 2h with shaking (120 rpm) and 
centrifugation was done at 3000xg for 15mins before uploading the samples into a vacuum 
concentrator (ThermoSavant AES2010 SpeedVac® System). Medium speed and heat conditions 
were applied. After evaporation, sterile deionized water (1 ml) was added to all samples before 
being stored at 4oC until needed. 
 
2.23 Nuclear magnetic resonance spectroscopy (NMR) 
 
The desired samples were mixed with an equal volume of methanol. Control; methanol only. 
Samples were centrifuged at 3000xg for 15mins and uploaded into ThermoSavant AES2010 
SpeedVac® System.  
NMR was performed at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University 
of Strathclyde, Glasgow. Respective samples were re-dissolved in 600 µl of Sigma-Aldrich 
Dimethyl Sulfoxide-d6 (DMSO-d6). For optimum dissolution, the samples were placed in a water 
bath for 3mins at 40oC then transferred to Sigma-Aldrich 5mm NMR tubes. The samples were 
vortexed for few seconds. The NMR tubes were wiped off with a cloth before being placed in a 
spinner in order to eliminate any fingerprints which could interfere with the analysis. The NMR 
tubes were placed into a probe gauge and uploaded into the auto-sampler before being ready for 
analysis using JEOL AS400 NMR (Figure 2.10). NMR processing was done using the Mnova 
10.0.1 software. 
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Figure 2.10: An overview of preparation steps leading to NMR spectroscopy. The respective samples were re-
dissolved in 600 µl of DMSO-d6 and placed in a water bath (3mins at 40oC). The samples were transferred to 5mm 
NMR tubes and mixed using a vortex for few seconds. The NMR tubes were placed into a probe gauge and uploaded 
into the auto-sampler before being ready for analysis using JEOL AS400 NMR. 
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CHAPTER 3: PROPERTIES OF THE  
SECRETED ANTIBACTERIAL ACTIVITY 
 
3.1 Introduction  
 
An environmental strain of S. plymuthica (Figure 3.1) isolated from the surface of the seaweed 
Ascophyllum nodosum has been shown to produce antibacterial activity against Gram-positive 
bacteria. This activity could be detected on agar plates after growing the microorganism 
aerobically in nutrient broth media NB for 18h at room temperature RT with shaking (120 rpm). 
The presence of inhibitory activity was assessed as previously mentioned in Section 2.5 against an 
appropriate target strain in this case; the Gram-positive bacterial strain (F) (Figure 3.2). 
 A previous study reported the isolation of S. plymuthica KmR transposon mutants deficient in the 
activity detected on agar plates but possessed another activity secreted in liquid media. Those 
mutants had Tn5 insertions into genes encoding polyketide synthases AlThubiani, (2013). The aim 
of this study is to investigate the production of the secreted antimicrobial activity in liquid media.  
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Figure 3.1: Colony morphology of the wild type strain S. plymuthica compromising small to medium mucoid orange 
shiny colonies on nutrient agar plate after growing for 18h at room temperature.  
 
 
 
Figure 3.2: The antibacterial activity of the wild type strain S. plymuthica towards the Gram-positive strain (F); 
NA(RT/24h). This image is a representative image of 3 replicates. 
 
A zone of inhibition 
created by 20 µl of 
an overnight culture 
of S. plymuthica 
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3.2 Optimization of secreted  antibacterial production 
 
3.2.1 Preparation of cell-free culture supernatants (CFCS) 
 
In order to investigate the secreted antibacterial activity of S. plymuthica, it was essential to prepare 
a cell-free culture supernatant CFCS that contained this activity. This was done by cultivating the 
antibacterial producing strain in 500 ml flasks with 100 ml of nutrient broth NB at 25oC for 48h 
with shaking (120 rpm) followed by centrifugation (3000x g at 4oC for 15mins). The culture 
supernatant of the antibacterial producing stain was collected and distributed into two groups.  
The effect of two sterilization approaches was investigated in order to establish the best method to 
eliminate remaining S. plymuthica cells and prepare a CFCS that contains the desired antibacterial 
activity. The first group of the CFCS was sterilized by different heat-treatments (60oC, 70oC, 80oC, 
90oC, 100oC) for 10mins. While, the second group of the CFCS was filter-sterilized using a 0.2 
µm cellulose acetate filter. The presence of activity was assessed against the Gram-positive strain 
(F).  
Results showed that at 60oC and 70oC the CFCS produced activity against the Gram-positive strain 
with an inhibition zone diameter of 11.3 mm. While, at 80oC and 90oC produced an inhibition zone 
diameter of 11.0 mm. There was a slight decrease in activity at 100oC with an inhibition zone 
diameter of 10.6 mm (Table 3.1). Results also showed that filter-sterilization does not inhibit or 
reduce the activity present in the CFCS (Figure 3.3). For the purpose of this study, heat-sterilization 
at 70oC was used as the main temperature for sterilizing the culture supernatant.  
The CFCS maintained its activity against the Gram-positive strain; the CFCS sample previously 
subjected to sterilization at (100oC) was autoclaved (121oC/15mins). The sample produced an 
inhibition zone diameter of 10.6 mm (Figure 3.4) which indicates that the secreted antibacterial is 
thermo-stable and tolerates autoclaving temperatures. 
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Table 3.1: Effect of heat-treatment on the secreted antibacterial activity. The activity is assessed 
against the Gram-positive strain (F). Inhibition zone sizes are in millimeters. Data shown are the 
means ± SD, n=3 
 
Temperature  Inhibition zone 
60oC 11.3±0.57 
70oC 11.3±1.15 
80oC 11±1.0 
90oC 11±0 
100oC 10.6±0.57 
121oC 10.6±0.57 
 
 
 
Figure 3.3: Demonstration of the  inhibitory activity of S. plymuthica CFCS against the Gram-positive strain (F) ; NA 
(RT/24h). The strain was cultivated in NB broth at 25oC for 48h with shaking (120 rpm).The bacterial culture was 
centrifuged (3000x g at 4oC for 15mins).The supernatant was collected and sterlized via two methods. A; a zone of 
inhbtion (12.0 mm in diamter) obtained via filter sterilizing S. plymuthica culture supernatant through a 0.2 µm 
cellulose acetate filter. B; a zone of inhbtion (11.0 mm in diamter) obtained via heat sterlizion of S. plymuthica culture 
supernatant. This image is a representative image of three replicates. 
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Figure 3.4: The thermo-stability of the secreted antibacterial activity. The CFCS of the antibacterial producing strain; 
S. plymuthica was autoclaved (121oC/15mins) and the presence of activity was assessed against the Gram-positive 
strain (F); NA(RT/24h). This image is a representative image of 3 replicates. 
 
 
3.2.2 Influence of incubation period on the production of secreted antibacterial activity 
 
The influence of incubation period on the production and amount of inhibitory activity detected in 
the CFCS was investigated in order to establish the optimum incubation period for the production 
of antibacterial activity in S. plymuthica culture supernatant. The antibacterial producing strain 
was incubated at the following incubation periods: 24h, 48h, 72h, 96h and 120h and the presence 
of activity was assessed against (F). Results showed that the inhibitory activity was produced after 
24h of cultivation and the CFCS produced an inhibition zone diameter of 8.3 mm against the Gram-
positive strain. The highest amount of antibacterial activity detected in the CFCS was after 48h 
and 72h of cultivation with inhibition zones diameter of 8.6 and 9.0 mm respectively. However, 
the amount of inhibitory activity in the CFCS was decreased after a cultivation period of 96h and 
120h with inhibition zones diameter of 8.3 and 7.0 mm respectively (Table 3.2). These results 
indicate that (48-72h) is the optimum incubation period for the production of secreted antibacterial 
activity detected in the CFCS; which could be the stationary phase for the antibacterial producing 
strain. 
 
An 11.0 mm 
zone of 
inhibition    
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Table 3.2: The influence of incubation period on the production of secreted antibacterial activity. 
The activity is assessed against the Gram-positive strain (F). Inhibition zone sizes are in 
millimeters. Data shown are the means ± SD, n=3 
 
Incubation period (hours) Inhibition zone 
24h 8.3±0.33 
48h 8.6±0.33 
72h 9.0±0 
96h 8.3±0.33 
120h 7.0±0 
 
 
3.2.3 Influence of cultivation temperatures and media composition on the production of secreted 
antibacterial activity 
 
In order to establish the optimum medium for the production of the secreted antibacterial activity. 
The antimicrobial producing strain S. plymuthica was inoculated in 250 ml sterilized flasks 
containing 20 ml of different broth media. Those included: NB, LB, BHI and MRS. Bacterial 
cultures were incubated aerobically across the following temperatures (16oC, RT, 30oC, 35oC) for 
72h with shaking 120 rpm. Bacterial cultures were centrifuged at (3000x g/ 15mins) and the 
supernatants were collected followed by heat-sterilization (70oC/10mins). The presence of activity 
was assessed against the following Gram-positive strains: S. aureus, B. cereus, B. subtilis and (F). 
Control broth media without bacterial cells were similarly tested.  
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3.2.3.1 The influence of media composition at 16oC on the production of secreted antibacterial 
activity 
 
At 16oC, all CFCS obtained from broth media produced inhibitory activity against the Gram-
positive strains (Table 3.3). The best broth media for the production of antibacterial activity 
detected in the CFCS was MRS, followed by BHI, NB then LB. The CFCS obtained from MRS 
broth produced the highest amount of inhibitory activity and showed inhibition zones diameter of 
14.3, 16.3, 17.3 and 12.6 mm against S. aureus, B. cereus, B. subtilis and (F) respectively.  
The activity of the CFCS obtained from BHI broth produced activity against B. subtilis and (F) 
with inhibition zones diameter of 15.3 and 10.3 mm respectively. The CFCS obtained from BHI 
broth produced intermediate activity against S. aureus and B. cereus with inhibition zones diameter 
of 11.0 mm. 
The CFCS obtained from NB broth showed intermediate inhibitory activity against B. subtilis and 
(F) with inhibition zones diameter of 11.6 and 8.3 mm respectively. The lowest activity detected 
in the CFCS from NB broth was against S. aureus and B. cereus with inhibition zones diameter of 
3.3 and 6.0 mm respectively.  
LB broth was the least suitable medium for the production of inhibitory activity. The CFCS 
obtained from LB broth produced intermediate activity against B. subtilis and (F) with inhibition 
zones diameter of 10.3 and 9.0 mm. The lowest activity detected in the CFCS from LB was against 
S. aureus and B. cereus with inhibition zones diameter of 3.6 and 3.3 mm respectively. These 
results indicate that at 16oC, MRS and BHI are the optimum broth media for the production of 
inhibitory activity detected in the CFCS. Results also showed that at 16oC, B. cereus and B. subtilis 
are the most sensitive strains to the inhibitory activity. 
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Table 3.3:  The influence of media composition at 16oC on the production of secreted antibacterial 
activity. The activity is assessed against indicator Gram-positive bacteria. Inhibition zone sizes are 
in millimeters. Data shown are the means ± SD, n=3 
 
 Inhibition zone 
Media 
broth  
S. aureus B. cereus B. subtilis (F) 
LB 3.6±6.4 3.3±5.8 10.3±1.2 9.0±1.7 
NB 3.3±5.8 6.0±5.2 11.6±2.1 8.3±1.5 
BHI 11.0±2.0 11.0±1.0 15.3±4.5 10.3±2.5 
MRS 14.3±1.5 16.3±3.5 17.3±4.6 12.6±2.3 
 
 
3.2.3.2 The influence of media composition at RT on the production of secreted antibacterial 
activity 
 
At room temperature (RT), not all CFCS obtained from broth media produced inhibitory activity 
against the Gram-positive indicator strains (Table 3.4). CFCS obtained from LB broth media only 
produced activity against B. subtilis with an inhibition zone diameter of 10.3 mm. The lowest 
recorded activity was by the CFCS from NB broth with inhibition zones diameter of 6.6 and 3.3 
mm against B. subtilis and B. cereus respectively and an inhibition zone diameter of 3.0 mm 
against (F) and S. aureus. The CFCS obtained from BHI broth produced intermediate activity 
against B. subtilis and (F) with inhibition zones diameter of 11.3 and 9.3 mm respectively while, 
produced low activity against B. cereus and S. aureus with inhibition zones diameter of 7.0 and 
3.6 mm respectively. The CFCS obtained from MRS broth produced the highest amount of 
inhibitory activity with inhibition zones diameter of 12.6, 10.6, 11.0 and 10.0 mm against S. 
aureus, B. cereus, B. subtilis and (F) respectively. These results indicate that at RT, LB broth is 
the least suitable media for the production of antibacterial activity detected in the CFCS. The best 
broth media for the production of antibacterial activity detected in the CFCS is M.R.S and BHI followed 
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by NB broth. Results also showed that at RT, S. aureus and B. subtilis are the most sensitive strains to the 
inhibitory activity of the CFCS.  
 
3.2.3.3 The influence of media composition at 30oC and 35oC on the production of secreted 
antibacterial activity 
 
At 30oC, the only recorded activity was from the CFCS obtained from MRS broth media with 
inhibition zones diameter of 6.6, 9.0, 10.3 and 10.6 mm against B. cereus, (F), B. subtilis and S. 
aureus respectively (Table 3.5). Also, at 35oC, there was no presence of inhibitory activity in the 
CFCS obtained from any of the broth media against the Gram-positive indicator strains.  
 
 
Table 3.4: The influence of media composition at RT on the production of secreted antibacterial 
activity. The activity is assessed against indicator Gram-positive bacteria. Inhibition zone sizes are 
in millimeters Data shown are the means ± SD, n=3  
 
 Inhibition zone 
Media 
broth  
S. aureus B. cereus B. subtilis (F) 
LB 0 0 10.3±1.5 0 
NB 3±5.2 3.3±5.8 6.6±5.8 3±5.2 
BHI 3.6±6.4 7±6.1 11.3±0.6 9.3±1.5 
MRS 12.6±1.5 10.6±1.2 11.0±1.0 10±1.0 
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Table 3.5:  The influence of media composition at 30oC on the production of secreted antibacterial 
activity. The activity is assessed against indicator Gram-positive bacteria. Inhibition zone sizes are 
in millimeters. Data shown are the means ± SD, n=3 
 
 Inhibition zone 
Media 
broth  
S. aureus B. cereus B. subtilis (F) 
LB 0 0 0 0 
NB 0 0 0 0 
BHI 0 0 0 0 
MRS 10.6±1.2 6.6±5.9 10.3±2.1 9.0±0 
 
  
3.2.4 Influence of different growth environments on secreted antibacterial production 
  
In order to establish the best growth environment for the production of secreted antibacterial 
activity detected in the CFCS. The antibacterial producing strain S. plymuthica was cultured under 
different conditions; (96 well-plates, centrifuge tubes and glass flasks). Incubation was done 
aerobically at room temperature for 72h with shaking (120 rpm). The strain was inoculated in MRS 
broth since it was established that it is the optimum growth medium for the production of 
antibacterial activity (Section 3.2.3) and the presence of antibacterial activity was assessed against 
the Gram-positive strain (F). Results showed that growing the antimicrobial producing strain in 96 
well-plates which contain ~300 µl of broth medium produced inconsistent results; making it very 
difficult to detect zones of inhibition.  Likewise, growing the antibacterial producing strain in 
centrifuge tubes (50 ml) containing 5 ml of MRS broth also produced inconsistent results and in 
many cases lack of inhibitory activity. The optimum growth environment for the production of 
secreted antibacterial activity was 250 ml flasks containing 20 ml of MRS broth medium. The 
CFCS produced inhibition zones diameter of 10±1 (Table 3.6). These results indicate that the 
production of antibacterial activity is influenced by growth conditions and aeration availability. 
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Table 3.6: The influence of different growth environments on the production of secreted 
antibacterial activity. The activity is assessed against (F). (±) inconclusive results, (+++) strong 
activity. N=3 
 
Growth environment Presence of inhibitory activity 
96 well- plates ± 
Centrifuge tubes (50 ml) ± 
Glass flasks (250 ml) +++ 
 
 
 
3.3 Characterization of the secreted antibacterial activity 
 
3.3.1 Effect of storage on the stability of secreted antibacterial activity  
 
The effect of storage on the stability of secreted antibacterial activity was studied by preserving 
the CFCS at 4oC for 7 days and recording the presence of activity against the Gram-positive 
indicator strain (F). Results showed that the inhibitory activity of the CFCS is affected by storage 
and decreases over time. The inhibition zones diameter decreased from 12.3 mm at day zero to 7.6 
mm at day 7 as shown in the following table: 
 
Table 3.7: The effect of storage at 4oC on the stability of secreted antibacterial activity. The activity 
is assessed against the Gram-positive strain (F). Inhibition zone sizes are in millimeters.   Data 
shown are the mean ± SD, n=3 
 
Day inhibition zone 
Zero  12.3 ± 1.5 
Day 5  11.6 ± 0.5 
Day 7  7.6 ± 6.6  
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3.3.2 Effect of Proteinase K and TWEEN® 20 on the stability of the secreted antibacterial activity 
 
The effect of Proteinase K on the stability of the secreted antibacterial activity was investigated in 
order to give an insight to the nature of the activity in the CFCS. The CFCS (100 µl) was mixed 
with (80 µl) of Proteinase K stock solution (20 mg/ml) and sterile distilled water (20µl) and 
incubated for 3h at 37oC and as a control an identical volume of a diluted CFCS was incubated 
without Proteinase K. The presence of activity was assessed against (F). Results showed that both 
the CFCS and the control sample produced zones of inhibition against the Gram-positive strain 
with inhibition zones diameter of 14.3±3.7 and 15±3.6 respectively (Figure 3.5). These results 
indicate that the antibacterial activity of the CFCS is resistant to Proteinase K and unlikely to be a 
protein. 
Regarding investigating the effect of the detergent TWEEN® 20 on the stability of the secreted 
antibacterial activity. This was done as follows: The CFCS was mixed with an equal volume of 
the detergent 1 % (v/v). Controls; positive control: CFCS without TWEEN® 20 and negative 
control: TWEEN® 20 only. All samples were incubated at 37oC for 3h and the presence of activity 
was assessed against the Gram-positive strain (F). Results showed that the inhibitory activity of 
the CFCS was not affected by the detergent. The CFCS produced activity with an inhibition zone 
diameter of 14.5 mm. The positive control (CFCS without detergent) produced an inhibition zone 
diameter of 15.0 mm (data not shown) while, the negative control (TWEEN® 20 only) showed no 
signs of inhibitory activity (Figure 3.6). 
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Figure 3.5: The effect of Proteinase K on the stability of secreted antibacterial activity. The CFCS was incubated with 
Proteinase K for 3h at 37oC. The presence of activity was assessed against the Gram-positive strain (F); NA (RT/24h). 
A; zone of inhibition (19.0 mm) produced by the control (CFCS without Proteinase K). B; zone of inhibition (17.0 
mm) produced by the (CFCS + proteinase K). This image is a representative image of 3 replicates.  
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Figure 3.6: The effect of the detergent (TWEEN® 20) on the stability of secreted antibacterial activity. The CFCS was 
mixed with an equal volume of the detergent and incubated for 3h at 37oC. Negative Control; (detergent only). The 
presence of activity was assessed against the Gram-positive strain (F); NA (RT/24h). A; zone of inhibition (14.0 mm) 
produced by the CFCS after incubation with TWEEN® 20, B; lack of inhibitory activity of the control (TWEEN® 20). 
This image is a representative image of three replicates. 
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3.3.3 Effect of pH on the stability of the secreted antibacterial activity  
 
The effect of pH on the stability of secreted antibacterial activity detected in the CFCS was 
investigated as follows: A fresh sample of the CFCS (30 ml) was distributed into 3 groups and 
named A, B and C. The pH of the CFCS was measured (pH 7.3±0.2) and recorded as initial pH. 
Group A was subjected to acidic conditions by adjusting the pH to 5 using HCl (1M). Group B 
was subjected to alkaline conditions by increasing the pH to 9 using NaOH (1M). Group C was 
the control sample (The CFCS without any changes to the pH). All samples were incubated at 
22oC for 2h with shaking (120 rpm). The pH of samples (A) and (B) were returned to the initial 
pH using HCl and NaOH. The presence of activity in all samples was assessed against the Gram-
positive strain (F). Results showed that all samples produced activity against the indicator strain 
(Table 3.8). The CFCS produced activity with inhibition zones diameter of 11.0 mm at pH 5 and 
10.0 mm at pH 9. The positive control; (CFCS without pH changing) produced activity with an 
inhibition zone diameter of 13.3 mm in diameter. These results indicate that the antibacterial 
activity is affected by changing the pH of the CFCS. 
 
 
Table 3.8: The effect of pH on the stability of secreted antibacterial activity. The activity is 
assessed against the Gram-positive strain (F); NA (RT/24h). Inhibition zone sizes are in 
millimeters. Data shown are the mean ± SD, n=3  
 
pH Inhibition zone 
pH 5 11 ± 0 
pH 7.3 ± 0.2 13.3 ± 0.57 
pH 9 10 ± 0  
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3.3.4 Effect of Tris buffer on the stability of secreted antibacterial activity 
 
Tris-buffer was initially chosen to maintain the secreted antibacterial activity since it was 
established that the activity decreases over time at 4oC (Section 3.3.1). The secreted antibacterial 
activity of the concentrated culture supernatant CCS (Section 5.1) was investigated in order to 
establish if the activity is affected by Tris-buffer pH 7.0; (50 mM), NaCl (50 mM), Glycerol (5%) 
and EDTA (2 mM).  
The activity of the CCS was initially assessed against the Gram-positive strain (F) prior to 
incubation with Tris-buffer. The CCS produced inhibition zones diameter of 14.3±4.9 mm. The 
Tris-buffer was added to the CCS (10:1; Tris-buffer: sample) and incubated for 2h at 21oC with 
shaking 120 rpm followed by centrifugation for 15mins. The supernatants (soluble fractions) were 
collected and placed into new centrifuge tubes and the precipitates were re-suspended in 1 ml of 
sterile deionized water. 
 The presence of activity in all samples was assessed as mentioned above. The CCS sample 
(soluble and precipitates fractions) produced activity against the Gram–positive strain with 
inhibition zones diameter of 10.0±0 and 10.3±0.6 mm respectively (Figure 3.7). These results 
indicate that the secreted bacterial activity was affected by the buffer making it an unsuitable 
choice to be used as a preservative. Also, the observed precipitate might be due to the presence of 
specific Serratia enzymes that metabolize organic acids and glycerol causing a precipitation 
reaction. 
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Figure 3.7: The Effect of Tris-buffer on the stability of secreted antibacterial activity. A Tris-buffer was incubated 
with the CCS (10:1) followed by incubation at 21oC for 2h with shaking (120 rpm) then centrifugation for 15mins. 
The supernatant (Soluble fraction) was collected and the precipitate was re-suspended in 1 ml of sterile deionized 
water. The presence of activity was assessed against the Gram-positive strain (F). A; zone of inhibition (10.0 mm) 
produced by the soluble fraction. B; zone of inhibition (11.0 mm) produced by the precipitate fraction. This image is 
a representative image of 3 replicates. 
 
 
3.3.5 Estimation of the molecular weight of the secreted antibacterial compound(s) 
 
An ultra-filtration technique was used to estimate the size of the secreted antimicrobial 
compound(s) present in the culture supernatant of the antibacterial producing strain S. plymuthica. 
A centrifugal device with a 10,000 Dalton molecular weight cut-off membrane (MWCO) was used 
and centrifugation conditions were applied appropriately according to manufacturer's instructions.  
Centrifugation produced two fractions, a retained fraction and a flow through fraction; which for 
the purpose of this experiment were named Fractions A and B respectively. The presence of 
activity in the fractions was assessed against (F). Both fractions A and B produced activity against 
the Gram-positive strain with inhibition zones diameter of 15.0 mm±1.0 and 10.6 mm±9.3 
respectively. These results might indicate the presence of two secreted antimicrobial compounds 
in the CFCS. A compound with a molecular weight ≥ 10,000 Daltons and a compound with a 
molecular weight < 10.000 Daltons.  
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In order to have an approximate size of the secreted antibacterial compound(s), another centrifugal 
device with a lower molecular cut-off was used (3000 MWCO) (Figure 3.8). Centrifugation also 
resulted in the production of two fractions. The retained fraction was named (Fraction C) while 
the flow through was named (Fraction D). The presence of activity was assessed against (F). 
Results showed that while Fraction (C) produced inhibitory activity with an inhibition zone 
diameter of 14.3±1.5 mm, (Fraction D) did not show any signs of activity (Figure 3.9). These 
results indicate the presence of two secreted antibacterial compounds in the CFCS, a compound 
with a molecular weight ≥10,000 Daltons and a compound with a molecular weight >3000 and 
<10,000 Daltons. Also, it is possible that there is only one antibacterial compound with portion 
forming larger aggregates. 
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Figure 3.8: A centrifugal filter with a molecular weight exclusion of 3000 Daltons was used in this study to estimate 
the size of the secreted antibacterial compound (s) present in the CFCS. The presence of activity in both fractions was 
assessed against the Gram-positive strain (F); NA(RT/24h). Fraction C produced inhibitory activity against the Gram-
positive strain however, fraction D did not show any signs of activity which indicates that the size of the secreted 
antibacterial compound(s) present in the CFCS is > 3000 Daltons. 
Fraction D 
Fraction C 
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Figure 3.9: The activity of the CFCS retained (fraction C) and the flow through fraction (Fraction D) obtained via 
ultra-filtration using a centrifugal filter with a molecular weight exclusion of 3000 Daltons against the indicator strain 
(F); NA (RT/24h). A; lack of inhibitory activity in the flow through fraction, B; zone of inhibition (16.0 mm) produced 
by the retained fraction. This image is a representative image of 3 replicates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
80 
 
3.3.6 Measuring the effect of antibacterial activity on bacterial growth 
 
The biological nature of the secreted antibacterial activity of the CFCS was investigated to 
determine whether it has a bacteriostatic or a bactericidal effect. This was done as previously 
mentioned in Section 2.11.2 followed by the addition of different volumes of the CFCS (20,60,180, 
540 and 1620 μl) to the cells of the Gram-positive strain B. cereus. All samples were incubated at 
30oC for 2h. As a control; (the cells of B. cereus were equally treated but without the CFCS). A 
series of 10-fold serial dilutions using sterile MRD were prepared from the samples and 100 μl of 
each dilution was plated onto nutrient agar plates and incubated at room temperature for 24h. 
Results are displayed in Figure 3.10 and showing the bactericidal activity of the CFCS; the larger 
the volume of CFCS added to the cells the lower the number of surviving colonies. 
 
 
 
Figure 3.10: The bactericidal activity of the secreted antibacterial compound(s) present in the CFCS against the Gram-
positive strain B. cereus. Different volumes of the CFCS were added to the cells of B. cereus. Control (B. cereus cells 
without CFCS). Serial dilutions (10 Fold Dilutions) were prepared and 100 μl of each dilution was plated onto NA 
plates and incubated at (RT/24h). Data represents the means. N=2. 
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3.3.7 Spectrum of secreted antibacterial activity 
 
The CFCS was investigated to study the spectrum of antibacterial activity and to establish wither 
it is restricted to Gram-positive bacteria. The activity of the CFCS was tested against the following 
strains previously mentioned in Table 2.1. These included, P. aeruginosa, K. pneumonia, S. 
marcescens, E. coli, C. tropicalis, S. diastaticus, C. krusei, S. cerevisiae and E. faecalis and (S). 
The following Gram-positive bacteria S. aureus, B. cereus, B. subtilis and (F) were used as 
controls. Spot agar assays were performed using NA plates for bacteria and YPD plates for the 
yeast and fungi and incubated appropriately. 
Results showed that the CFCS did not show any activity against any of the Gram-negative bacteria 
or fungal and yeast strains. Surprisingly, the CFCS also did not show any activity against the Gram-
positive strain E. faecalis. The spectrum of the secreted antibacterial activity present in the CFCS 
is demonstrated in Table 3.9. These results indicate that the secreted antibacterial activity is 
species-specific targeting Gram-positive bacteria in particular those belonging to Bacillaceae 
confirming the results previously mentioned in Section 3.2.3. 
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Table 3.9: The spectrum of inhibitory activity of the secreted antibacterial compound(s) (+++) 
strong inhibitory activity, (-) no inhibitory activity. N=3 
 
Indicator strain   Inhibitory activity  
(F)  +++ 
Pseudomonas aeruginosa -  
B. cereus +++ 
S. aureus +++ 
B. subtilis +++ 
(S) - 
Klebsiella pneumoniae  -  
Enterococcus faecalis - 
Serratia marcescens - 
Saccharomyces cerevisiae - 
Candida tropicalis - 
Candida krusei  - 
Saccharomyces diastaticus - 
Escherichia coli  - 
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CHAPTER 4: ISOLATION OF MUTANTS DEFICIENT IN 
THE SECRETED ANTIBACTERIAL ACTIVITY 
 
4.1 Transposon mutagenesis 
 
In this study transposon mutagenesis (Figure 4.1) was performed to identify gene(s) responsible 
for the production of the secreted antibacterial activity detected in the CFCS by screening for 
mutants that no longer secrete this activity, i.e. fail to inhibit the growth of Gram-positive indicator 
strains.  
The initial hypothesis was that if the two activities produced by S. plymuthica are related then all 
or at least some mutants that are selected as being unable to produce the secreted activity should 
also be deficient in the activity identified on agar plates. On the other hand, if the two activities 
are different then transposon mutagenesis would result in the production of new mutants; mutants 
that possess the antibacterial activity detected on agar plates but deficient in the secreted activity. 
The transposon was delivered by conjugation between the wild type strain S. plymuthica and an E. 
coli strain carrying plasmid pRL27 (4080 bp; KmR-oriR6K) which contains a mini-Tn5 element 
(1800 bp) that encodes resistance to kanamycin (Figure 4.2). Preliminary identification of a 
successful conjugation was done by counting the number of KmR colonies as illustrated in Figure 
4.3. 
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Figure 4.1: An illustration of transposon mutagenesis performed in this study via conjugation between the wild type 
strain S. plymuthica and plasmid pRL27. The plasmid carries a mini-Tn5 transposon which encodes resistance to 
kanamycin KmR. Tn5 is a composite transposon in which antibiotic resistance genes are flanked by two inverted 
repeats elements. One of the inverted repeats encodes the protein transposase and both elements are bounded by 19-
bp end sequences. Tn5 transpose via conservative non-replicative cut-and-paste mechanism. Transposition starts when 
the transposase binds to the 19 bp end sequences leading to an oligomerization reaction and the formation of a synaptic 
complex. Next, a double strand breakage at both ends of the transposition synaptic complex defined by the end 
sequences occurs which leads to its release and insertion into the new target. The cleavage of strands at the target site 
is staggered site creating a characteristic 9 bp target site duplication (TSD) flanking the transposon (Haniford & Ellis, 
2015; Reznikoff et al., 1999; Bennett, 2008). 
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Figure 4.2: Demonstration of plasmid pRL27 used in transposon mutagenesis experiments. pRL27 carries a Tn5 
transposon which encodes resistance to kanamycin and contains an origin of replication (oriR6K) that allows cloning 
of transposon insertion sites. In conjugation the mobilization of the plasmid is via the origin of transfer (oriT) (Larsen 
et al., 2002; Hayes, 2003). 
 
Tn5 inverted 
repeats 
Tn5 inverted 
repeats 
The aph gene encodes 
resistance to 
kanamycin 
 
 
86 
 
 
Figure 4.3: A conjugation plate (NA+50µg/ml Kanamycin and 50 µg/ml Ampicillin) of S. plymuthica antibiotic 
resistant transconjugants (24h/RT). 
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4.2 Screening for mutants deficient in the secreted antibacterial activity  
 
Screening for mutants was preceded by the purification of S. plymuthica KmR colonies. This was 
done as follows: KmR mutants were picked aseptically and sub-cultured onto nutrient agar plates+ 
(50µg/ml Kanamycin) and incubated for 24h at RT. The KmR colonies were inoculated into 
centrifuge tubes (50 ml) containing 1 ml of MRS broth without antibiotic; since the transposase 
(Tnp) gene is located outside the inverted repeats thus preventing further transposition, ensuring 
the stability of the transposon insertion in the target gene (Dennis & Zylstra, 1998). Bacterial 
cultures of KmR colonies were incubated at 16oC with shaking 120 rpm for (48h-72h) followed by 
centrifugation at 3000x g for 15mins. The culture supernatants were collected and sterilized at 
70oC for 10mins then left to cool at RT for 15mins. Screening for mutants deficient in secreted 
antibacterial activity was done by performing spot agar assays against the Gram-positive strains 
B. cereus and (F). The CFCS of S. plymuthica KmR mutants (40 µl) was spotted onto nutrient agar 
NA square plates pre-spread with 300 µl of a fresh culture of the Gram-positive strains. The wild 
type S. plymuthica was used as positive control (Figure 4.4) and all plates were incubated at RT 
for 24h (Figure 4.5). Mutants deficient in the secreted antibacterial activity; lack of zones of 
inhibition against the indicator strains were isolated and subjected to further tests (Figure 4.6). 
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Figure 4.4: The phenotypic bioactivity of the environmental strain S. plymuthica against the indicator strain (F) NA; 
(24h/ RT). A; Production of inhibitory activity when S. plymuthica is grown on plates. B; Presence of inhibitory 
activity in the CFCS. 
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Figure 4.5: The results of screening for mutants deficient in the secreted antibacterial activity. S. plymuthica KmR 
mutants were inoculated in MRS broth; (16oC/48-72h). Mutants with a CFCS deficient in antibacterial activity; lack 
of zone of inhibition against the indicator strain B. cereus; NA(24h/RT) were considered potential mutants and 
subjected to further tests. labeled as A and B and by the arrows. 
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Figure 4.6: S. plymuthica KmR mutants deficient in the secreted antibacterial activity (A) were subjected to further 
tests. Those mutants were inoculated in NB broth and incubated at (RT/18h) with shaking 120 rpm. Mutants that 
produce antibacterial activity (B) against the indicator strain B. cereus; NA(24h/RT) were considered potential 
mutants.  
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In this study, 597 KmR transposon induced mutants were screened resulting in the isolation of two 
non-antibacterial producing strains named; M74 and M426. Those mutants lacked the secreted 
antibacterial activity in their CFCS. The Mutant strains exhibited different colony morphology, 
mutant M74 was pigmented as the parent strain and produced pink glistening colonies (Figure 4.7), 
while mutant M426 was non- pigmented and produced white mucoid colonies (Figures 4.8).  
In order to test the hypothesis previously mentioned in Section 4.1; the ability of the KmR 
transposon induced mutants M74 and M426 to produce antibacterial activity when grown on agar 
plates. This was done as follows: mutants M74 and M426 were inoculated in NB broth and 
incubated at RT for 18h with shaking 120 rpm and spot agar assays were performed using the 
mutants bacterial culture against the Gram-positive strains. Plates were incubated at RT for 24h. 
 Results showed the presence of inhibitory activity against the indicator strain. The phenotypic 
activities of M74 and M426 are demonstrated in Figures 4.9 and 4.10. 
For further confirmation, mutants deficient in antibacterial activity detected on agar plates obtained 
by AlThubiani, (2013), were tested against the Gram-positive strains using the mutants’ CFCS. 
Those mutants showed activity against the Gram-positive strains (Data not shown). These results 
indicate that S. plymuthica produce multiple antimicrobial compounds and the two observed 
activities are distinct.  
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Figure 4.7: Colony morphology of KmR transposon induced mutant M74 compromising small pink glistening 
colonies on nutrient agar plate NA after growing for 24hr at room temperature RT. 
 
 
 
Figure 4.8: Colony morphology of KmR transposon induced mutant M426 compromising small white mucoid colonies 
on nutrient agar plate NA after growing for 24h at room temperature RT. 
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Figure 4.9: The phenotypic bioactivity of the KmR transposon induced mutant M74 obtained in this study against the 
indicator strain B. cereus; NA; (24h/ RT). A; inhibitory activity produced by the mutant when grown on plates. B; 
lack of inhibitory activity in the mutant’s CFCS. 
 
 
 
Figure 4.10: The phenotypic bioactivity of KmR transposon induced mutant M426 against the Gram-positive strain B. 
cereus; NA; (24h/ RT). A; inhibitory activity produced by the mutant when grown on plates. B; lack of activity in the 
CFCS. 
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4.3 Detection of the KmR gene 
 
To verify that the observed phenotype of each mutant; M74 and M426 was indeed caused by Tn5 
transposon insertion; insertion of the KmR gene into the genome of S. plymuthica.  A PCR reaction 
was performed as previously described in Section 2.15 using primers (AGPT-F and AGPT-R) that 
anneal to the KmR gene (Larsen et al., 2002).  
The genomic DNA of the mutant strains was used as a template. Controls were also included; a 
positive control (plasmid PRL27, containing the KmR gene) and a negative control (genomic DNA 
of the wild type). Amplified PCR products were visualized via agarose gel electrophoresis as 
mentioned in Section 2.14.3 and a 1kb DNA Ladder was used as a marker. 
Results of gel electrophoresis of the PCR products showed the presence of bands measuring ~600 
bp corresponding to the PCR products of mutants M74, M426 and plasmid pRL27 (positive 
control) and confirming the presence of the KmR gene within the genomic DNA of the mutants. 
As expected, the PCR product of the wild type strain did not produce a band on gel electrophoresis 
as shown in the following figure: 
 
 
 
Figure 4.11: Agarose gel electrophoresis of the amplified KmR gene. A; 1 kb ladder, B; PCR product of pRL27 
(positive control), C; PCR product of the wild type strain S. plymuthica (negative control), lanes D and E; PCR 
products of KmR mutant M74, lanes F and G; PCR products of KmR mutant M426. 
Marker; 1 kb 
ladder 
~600 bp 
 
 
95 
 
4.4 Cloning and identification of transposon insertion sites 
 
Cloning and recovery of the transposon insertion and the flanking DNA was performed in order to 
identify gene(s) responsible for the production of the secreted antibacterial activity detected in the 
CFCS. This was done as follows: the genomic DNA of KmR mutants M74 and M426 was isolated 
using the Thermo Scientific GeneJET Genomic DNA Purification Kit as previously described in 
Section 2.14.1 and was followed by restriction enzyme digestion using the enzyme (BamHI) which 
does not cut within the transposon in order to produce a DNA fragment with the oriR6K origin, 
the aph gene and adjacent genomic DNA sequences. The digested DNA was subjected to a ligation 
reaction using the enzyme T4 DNA ligase which promotes self-ligation of the BamHI DNA 
fragments (Larsen et al., 2002). The efficiency of the methods was confirmed by the visualization 
of DNA via agarose gel electrophoresis. Both KmR mutants produced bands on agarose gels after 
Genomic DNA extraction and a smear after enzymatic digestion with BamHI as shown in the 
following figure: 
 
 
 
Figure 4.12: Agarose gel electrophoresis of kmR mutants obtained in this study after Genomic DNA extraction and 
enzymatic digestion with BamHI. A; 1 Kb ladder, B; Genomic DNA of mutant M74, C; digested Genomic DNA of 
mutant M74), D; Genomic DNA of mutant M426, E; digested Genomic DNA of mutant (M426). 
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After performing ligation reactions on digested genomic DNA of KmR mutants M74 and M426, 
Ligated DNA was introduced into the E. coli strain S17-1 λpir via electroporation. This strain 
contains the pir gene which allows circularized DNA fragments containing the transposon to 
replicate as pir-dependent plasmids (Kvitko et al., 2012).  
Despite several repeated attempts to clone M74 and M426 using home-made competent cells, 
cloning experiments were not successful. Hence, commercially available cells (TransforMax™ 
EC100D™ pir-116 electrocompetent E. coli) were used instead. However, cloning experiments 
were still not successful. Following this, the restriction enzyme EcoRI was used instead of BamHI 
in an attempt to identify and clone transposon insertion sites. It should be noted that there is an 
EcoRI site inside the right-side end of the Tn5 which does not cut inside the transposon flanking 
sequences allowing directional cloning (Tolonen et al., 2006; Choi et al., 2012; Erb et al., 2010; 
Salch & and Shaw, 1988).  
The genomic DNA of KmR mutants M74 and M426 were extracted as previously mentioned and 
enzymatically digested with EcoRI. The efficiency of the methods was confirmed via agarose gel 
electrophoresis (Figure 4.14). The Ligated- cut Genomic DNA of M74 and M426 was introduced 
into TransforMax™ EC100D™ pir-116 electrocompetent E. coli via electroporation as described 
in Section 2.19.3 and the following control provided by the manufacturer was included; 
[Transformation control (116+)].  
Using sterile glass beads, all samples; (100µl each) were plated onto LB plates supplemented with 
the antibiotic Km; (50μg/ml) and incubated for 24h at 37oC. The produced colonies were purified 
by sub-culturing onto new LB plates+ Km. Recombinant plasmids form KmR E. coli transformants 
cells were inoculated in LB broth+ km; 50μg/ml and incubated for 24h at 37oC followed by 
purification of plasmid DNA using the Thermo Scientific GeneJET Plasmid Miniprep Kit. 
Enzymatic digestion using EcoR1 was performed on the recombinant plasmids of mutants M74 
and M426 in order to confirm the presence of the genomic DNA flanking the transposon insertion 
site in pir-116 E. coli. Agarose gel electrophoresis of the digested recombinant plasmids confirmed 
a successful delivery of Tn5 into pir-116 E. coli (Figure 4.15). Identification of transposon 
insertion sites was preceded by DNA sequencing at Edinburgh Genomics. This was done as 
described in Section 2.20.2 using primers TPNRL17-1 and TPNRL13-2 that anneal to the origin 
of replication and the KmR gene of the transposon (Figure 4.16) (Bruckbauer et al., 2015; Zhang 
et al., 2000; Buchan et al., 2008).  
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Only DNA sequencing of the recombinant plasmid from M426 was successful. Nucleotide 
sequences of DNA segment flanking the transposon insertion was compared with those in the 
databases of the National Center for Biotechnology Information (NCBI) using the query BLASTX. 
Results showed that the Tn5 has inserted into a gene that encodes a PKSs with 70% identity (Table 
4.1). Amino acid sequence of Polyketide synthase of the flanking region of transposon insertion 
of mutant M426 reveals how well the query sequence matches the subject sequence in the database 
(Figure 4.17). 
Based on the above results a conclusion was drawn with two possibilities regarding the 
antibacterial activity of the wild type strain: (1) The presence of two separate biochemical 
pathways leading to two distinct activities; the activity detected on agar plates and the other 
secreted activity detected in the CFCS (2) There is a branched biochemical pathway with one 
branch leading to the activity observed on the plates and another branch leading to the secreted 
activity. All steps leading to cloning and identification of transposon insertion site are illustrated 
in Figure 4.13. 
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Figure 4.13: An illustration of the steps of cloning and identification of transposon insertion sites. The genomic DNA 
of KmR mutant M426 was extracted followed by enzymatic digestion with EcoRI. Ligated Genomic DNA was 
introduced into TransforMax™ EC100D™ pir-116 electrocompetent E. coli via electroporation. The samples were 
plated onto LB plates +Km; (50μg/ml) followed by incubation (24h/37oC). Recombinant plasmids form KmR E. coli 
transformants cells were purified in order to be sequenced using primers TPNRL17-1 and TPNRL13-2 that anneal to 
the origin of replication and the KmR gene of the transposon. 
 
 
 
Figure 4.14: Agarose gel electrophoresis of KmR mutants obtained in this study after Genomic DNA extraction and   
EcoRI digestion. A; 1 Kb ladder, B; Genomic DNA of mutant M74, C; digested Genomic DNA of mutant M74, D; 
Genomic DNA of mutant M 426, E; digested Genomic DNA of mutant M426. 
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Figure 4.15: Agarose gel electrophoresis of EcoRI uncut and cut recombinant plasmids (WP1-WP5) of mutant M426. 
Enzymatic digestion was performed on recombinant plasmids in order to confirm the presence of the transposon insert 
in the vector pir-116 E. coli. Supercoiled DNA run faster than linear DNA making it difficult to determine the size of 
supercoiled DNA. Hence, a lower limit on the size is given. A; 1 Kb ladder. Lanes (B-F); uncut transposon 
recombinant plasmids (WP1-WP5), Lanes (G-K); cut transposon recombinant plasmids WP1-WP5. 
 
 
 
Figure 4.16:  Partial sequencing of the flanking genomic DNA of KmR recombinant plasmids obtained in this study   
was done using primers TPNRL17-1 and TPNRL13-2 that anneal to the origin of replication and the KmR gene of 
the transposon. 
 
 
 
 
 
 
 
 
~5500 bp 
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Table 4.1:  Results of BLASTX search obtained from the partial sequencing of the flanking 
genomic DNA of mutant M426 showing that the Tn5 has inserted into a gene resembling PKS 
 
Description 
 
 
Max 
score 
Total 
score 
Query 
cover 
E 
value 
Max 
identity 
Accession 
Polyketide synthase 
(Paenibacillus 
peoriae) 
 
91.7 91.7 62% 9e-20 70% WP_076265426.1 
Polyketide synthase 
(Paenibacillus 
peoriae) 
 
91.7 91.7 62% 9e-20 70% WP_075154433.1 
Polyketide synthase 
(Paenibacillus 
peoriae) 
91.7 91.7 62% 9e-20 70% WP_064962241.1 
 
 
 
 
Figure 4.17: Amino acid sequence of Polyketide synthase obtained from Blastx analysis (NCBI) of the flanking region 
of transposon insertion of mutant M426 using TPNRL17-1 primer in a comparison with the database. 
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CHAPTER 5: CHEMICAL PROFILING OF 
THE SECRETED ANTIBACTERIAL ACTIVITY 
 
5.1 Concentration of secreted antibacterial activity 
 
In order to further investigate the secreted antibacterial activity, freeze-drying was performed to 
concentrate the CFCS. This was done as follows: a fresh sample of the CFCS (50 ml) was 
distributed in shallow plates and placed at -20oC for 24h in preparation for freeze drying as 
previously mentioned in Section 2.21.2. A control was included; (50 ml of NB only). 
Concentrating the CFCS resulted in the production of a powder-like material (Figure 5.1) which 
was then re-suspended in 2 ml sterile deionized water; (resulting in a 25-fold concentration) and 
named concentrated culture supernatant or CCS. To avoid the presence of contamination, the re-
suspended CCS was sterilized using a 0.2 µm membrane filter and the presence of activity was 
assessed against the Gram-positive strain (F). The CCS produced activity with an inhibition zone 
diameter of 11.3 mm while, the negative control (concentrated NB) did not produce any activity 
(Figure 5.2).  
In this study, one of the initial attempts to concentrate the culture supernatant was by performing 
rotary evaporation as previously mentioned in Section 2. 21.1. The end result of this method was 
a brown gel-like material (Figure 5.3) which was removed and re-suspended in 2 ml of sterilized 
deionized water and stored at 4oC until needed. The presence of activity was assessed as previously 
mentioned above. The rotary evaporation concentrate produced activity with an inhibition zone 
diameter of 21.0 mm. To make sure that the white growth in the middle of the zone of inhibition 
is a precipitant and not contamination using a sterile cotton swab, the rotary evaporation 
concentrate was streaked onto an NA plate and incubated for 24h at RT. There was no presence of 
growth or colonies (Data not shown). Unfortunately, there was some problems regarding this 
method, it was time consuming; (5h) and it was difficult to remove the brown gel-like material 
from the rotary bulb due to its high viscosity. For these reasons, freeze drying was used as the main 
method to concentrate the CFCS. 
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Figure 5.1: Demonstration of the end-product of concentrating the CFCS. Concentrating the CFCS via freeze-drying 
resulted in the production of a powder-like material (A) which was re-suspended in 2 ml sterile deionized water and 
named concentrated culture supernatant CCS (B). 
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Figure 5.2: Demonstration of the antibacterial activity of the CCS against the Gram-positive strain (F); NA (RT/24h). 
A; zone of inhibition (12.0 mm) in diameter produced by the CCS. B; a nutrient agar plate showing lack of activity 
produced by the concentrated negative control (NB broth only) against the Gram-positive strain. This image is a 
representative image of 3 replicates. 
 
 
 
Figure 5.3: Demonstration of the result of concentrating the CFCS via rotary evaporation and the production of a 
brown gel-like material which was collected from the rotary bulb and re-suspended in sterile deionized water (2 ml). 
 
The end-product of 
concentrating the 
CFCS; a brown gel-
like material 
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5.2 Purification of the secreted antibacterial compound(s) by organic solvent extraction 
  
The secreted antibacterial compound(s) present in the CFCS was purified using methanol as 
previously mentioned in Section 2.22. Centrifugation resulted in the production of supernatants 
and pellets in all samples which were later named soluble and insoluble fractions respectively. The 
soluble fractions were placed into new centrifuge tubes before uploading all the samples into the 
ThermoSavant AES2010 SpeedVac® System to be evaporated to dryness in order to eliminate any 
traces of methanol. Sterile deionized water (1 ml) was added to all samples and the presence of 
activity was assessed against the Gram-positive strain (F). 
Results showed that all samples, excluding that of the negative control; (methanol directly spotted 
onto the plate) produced activity against the gram-positive strain; indicating the efficiency of the 
evaporation step (Table 5.1). The soluble and insoluble fractions of the positive control produced 
activity against the Gram-positive strain with inhibition zone diameters of 10.0 and 10.6 mm 
respectively (Figure 5.4). While, the soluble and insoluble fractions of the CCS produced activity 
with inhibition zone diameters of 12.3 and 11.6 mm respectively (Figure 5.5 and 5.6). These results 
might indicate that the secreted antibacterial compound(s) can aggregate or the presence of two 
secreted antibacterial compounds in the CFCS, one that is insoluble in methanol while the other is 
soluble in methanol. 
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Table 5.1: The inhibitory activity of the purified secreted antibacterial compound(s). The 
inhibitory activity was assessed against the Gram-positive strain (F). Inhibition zones are measured 
in millimeters. Data shown are the means ± SD, n=3 
 
Fractions  Inhibition zones 
Positive control (soluble fraction) 10.0 ± 0 
Positive control (insoluble fraction) 10.6 ± 1.1 
CCS (soluble fraction) 12.3 ± 1.1 
CCS (insoluble fraction) 11.6 ± 0.5 
Negative control (methanol only) 0 
 
 
 
 
Figure 5.4: The activity of the positive controls used in organic solvent extraction method against the Gram-positive 
strain (F); NA (RT/24h). A; a zone of inhibition (12.0 mm) in diameter produced by the insoluble fraction of the 
positive control. B; a zone of inhibition (10.0 mm) in diameter produced by soluble fraction of the positive control. 
This image is a representative image of 3 replicates. 
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Figure 5.5: The activity of the soluble fraction of the CCS against the Gram-positive strain (F). This image is a 
representative image of 3 replicates. 
 
 
 
Figure 5.6: The activity of the insoluble fraction of the CCS against the Gram-positive strain (F). This image is a 
representative image of 3 replicates. 
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5.3 NMR spectroscopy 
 
To get a closer understanding of the secreted antibacterial compound(s) an NMR was performed 
as follows: the activity of the CFCS and the CCS was initially assessed against the Gram-positive 
strain Bacillus cereus. Both samples produced activity with inhibition zones diameter of 10.0 mm. 
The CFCS and the CCS were mixed with equal volumes of methanol followed by centrifugation 
at (3000xg/15mins). The supernatants were placed into new centrifuge tubes and all samples were 
loaded into the ThermoSavant AES2010 SpeedVac® System to be evaporated to dryness in order 
to eliminate any traces of methanol. For the purpose of this experiment, the samples were named 
as follows: sample 1(soluble fraction of the CFCS), sample 2 (insoluble fraction of the CFCS), 
sample 3 (soluble fraction of the CCS) and sample 4 (insoluble fraction of the CCS). The samples 
were re-dissolved in 600 µl of DMSO in order to avoid the spectra to be dominated by the solvent 
signal then transferred to NMR tubes (5 mm) before analysis using JEOL AS400 NMR 
spectrometer. The spectrum of all samples showed a peak at 2.5 ppm corresponding to the 
deuterated solvent DMSO-d6 (Figure 5.7). 
 
 
 
108 
 
 
Figure 5.7: The NMR spectrum of the secreted antimicrobial compound(s) have two dimensions: the x axis 
corresponding to the frequency (ppm) and the Y axis corresponding to the intensity. The peak at 2.5 ppm is the DMSO 
signal. Samples were named as follows: [sample 1; soluble fraction of the CFCS, sample 2; insoluble fraction of the 
CFCS, sample 3; soluble fraction of the CCS and sample 4; insoluble fraction of the CCS]. The NMR spectrum of 
sample 3 showed peaks with high intensity at 3-5 ppm and peaks with smaller intensity at 7-8 ppm and 0-1 ppm 
corresponding to a polyketide structure. The NMR spectrum of sample1 showed peaks at 1-1.5 ppm and 3-3.5 ppm 
corresponding to a polyketide structure. The NMR spectrum of samples 2 and 4 showed peaks at 2.5 ppm 
corresponding to the DMSO. All other peaks shown on the spectra above did not correspond to any known compounds 
of interest. 
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The NMR spectrum of sample 3 showed peaks with high intensity at 3.0-5.0 ppm and peaks with 
smaller intensity at 7.0-8.0 ppm and 0-1.0 ppm corresponding to a polyketide structure with 
methyl, unsaturated hydroxyl units, respectively. On the other hand, the NMR spectrum of sample 
1 showed peaks with smaller intensity at 1.0-1.5 ppm and 3.0-3.5 ppm which might be due to the 
fact that the sample was diluted (not concentrated via freeze drying). Surprisingly, samples 2 and 
4 which were the insoluble fractions of the CFCS and CCS, showed no presence of any polyketide 
structure but merely a peak at 2.5 ppm corresponding to the solvent DMSO-d6 which verifies the 
hypothesized precipitation reaction produced by the antimicrobial producing strain previously 
mentioned in Section 3.3.4. 
A modular organization of the secreted antimicrobial compound(s) was created from the imposed 
spectra of sample1 (soluble fraction of CFCS) and sample 3 (soluble fraction of CCS) using the 
(Mnova 10.0.1) software (Figure 5.8). Results showed that sample 3 contains a secondary 
metabolite similar to that of erythromycin which is a polyketide produced by type I PKSs. This 
antimicrobial compound is synthesized via three enzymes DEBS1, DEBS2 and DEBS3.  
Results also showed the presence of another modular organization but did not reveal the end -
product of the biosynthetic pathway which confirms the presence of another secreted antibacterial 
compound, similar to rapamycin as indicated by the presence of double bonds at the 7.0-9.0 ppm 
region of the NMR spectrum. 
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Figure 5.8: NMR analysis of the secreted antimicrobial compound(s) in sample 1 (soluble fraction of the CFCS) and 
sample 3 (soluble fraction of the CCS). Upper graph; modular organization of the secreted antibacterial compound 
showing type I PKSs structure resembling erythromycin and incomplete modular organization of a second 
antibacterial compound similar to rapamycin. Lower graph; superimposed spectra of sample 1 (blue line) and sample 
3 (red line) showing a peak at 2.5 ppm corresponding to the DSMO-d6, a peak at 0.5-1.5ppm corresponding to methyl 
units, a peak at ~3-5 ppm corresponding to hydroxyl units and unsaturated moieties at 6-8.5 ppm. 
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5.3.1 COrrelation SpectroscopY (COSY) 
 
 In order to confirm the postulated structure of the secreted antibacterial compounds obtained from 
the 1H NMR results, a COSY NMR (25 scans) was performed on sample 3 (soluble fraction of 
CCS).  
The COSY spectrum (Figure 5.9) is a representative of an 1H-1H NMR spectrum which runs across 
a diagonal ridge from the upper right corner to the lower right corner of the plot. Each axis is 
calibrated based on the 1H chemical shift values (ppm) and can identify unknown compounds via 
spin–spin couplings of adjacent protons which is manifested as distinctive cross peak patterns (Xi 
et al., 2007). Interpretation of the results was done by extending the vertical and horizontal lines 
from each spot on the diagonal to its corresponding peak on each axis. It should be noted that the 
diagonal peaks are merely reference points. The COSY spectrum showed a correlation between 
the CHOH and alkyl units corresponding to 3.0-4.5 ppm and 1.0-2.5 ppm.  
The above results verify those shown in Section 4.4 in that the secreted antimicrobial compound(s) 
is synthesized by PKSs. Results also confirm the presence of two antimicrobial compounds in the 
CFCS; one or both responsible for the secreted antibacterial activity. 
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Figure 5.9: Results of COrrelation SpectroscopY COSY of sample 3 (soluble fraction of the CCS) which confirmed a 
correlation between CHOH moieties with the alkyl units as shown by the arrows that correspond with cross peaks 
observed in the spectrum highlighted with the same colour as the arrows. 
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CHAPTER 6: DISCUSSION AND CONCLUSION  
 
 6.1 General discussion 
 
The marine environment is an untapped resource of natural metabolites and encompasses an 
enormous level of rich ecological biodiversity. These compounds exhibit many bioactive 
properties as natural means of defense against predators (Ibrahim et al., 2014; Levy, 2002; Su et 
al., 2016; Vivas et al., 2000). Marine derived microbial secondary metabolites are attracting 
attention due to the rise of antibiotics resistance and the growing demand for finding new 
antibiotics to combat infectious diseases. These compounds are characterized by antibacterial, 
anticoagulant, anti-inflammatory, anti-fungal, antihelmintic, antiplatelet, antiprotozoal and 
antiviral activities as well as acting on the cardiovascular, immune and nervous systems with 
promising possibilities in marine biochemistry, microbiology and biotechnology as well as in 
pharmaceutical industry, drug development and research (Malve, 2016; Mayer et al., 2010; 
Kasanah & Hamann, 2004). 
Antimicrobial resistance is one of the biggest threats to global public health and efficient 
continuous collaborations between academics and industrial scientists is essential to ensure the 
success of marine natural products as novel therapeutic entities (Lehtinen et al., 2017; O'Connor, 
2015). Strains of the genus Serratia inhabit diverse environmental niches with numerous strains 
considered a reservoir of structurally unique and biologically significant novel secondary 
metabolites with potent activities. These include; anti-bacterial, anti-fungal, anti-protozoal, anti-
malarial and cyto-toxic activities (Bezawada et al., 2013; Gulani et al., 2012; Bhargavi & 
Prakasham, 2013). The production of some Serratia secondary metabolites is due to the presence 
of PKSs genes and secretion systems (Adam et al., 2016; Bhadra et al., 2005; Shang et al., 2017). 
The number of microbial compounds isolated from the marine environment continue to increase 
each year. Marine bacterial species produce novel bioactive compounds with numerous strains 
isolated from the surface of marine organisms such as algae. This study investigates the 
antibacterial activity of an environmental isolate of S. plymuthica isolated from the surface of the 
seaweed Ascophyllum nodosum from Aberdour beach, Scotland. The strain produces multiple 
antibacterial activities. An activity detected on agar plates and a secreted activity detected in the 
CFCS. This indicates that S. plymuthica produces antimicrobial compound(s) that can diffuse into 
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aqueous environments as well as compound(s) that remain closely bound to the outer cell surface 
and secreted into solid mediums. This phenotypic property might be a defensive mechanism to 
protect the antibacterial producing strain in its natural marine habitat due to the fact that 
antibacterial compound(s) bound to the cells can excrete slowly and continually into the 
environment preventing colonization by competitors, since a rapid release of antibacterial 
compound(s) would not provide a competitive advantage due to their immediate elimination   by 
seawater (Hosny et al., 2011).  
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6.2 Preparation of cell-free culture supernatants CFCS 
 
Since the aim of this study is to investigate the secreted antibacterial activity present in the CFCS 
of S. plymuthica, first it was essential to prepare a CFCS with the desired antibacterial activity. 
This was done by inoculating the antibacterial producing strain in an appropriate broth medium 
followed by incubation at 25oC for 48h. The bacterial culture was centrifuged, and the culture 
supernatant was heat-sterilized at 70oC for 10 mins in order to eliminate the presence of any 
remaining cells and the presence of activity was recorded as average zones of inhibition against 
the Gram-positive strain (F). 
The findings shown in Section 3.2.1 are similar to a study by (Someya & Kataoka, 2000) who 
reported the presence of two antifungal compounds in the culture supernatant of Serratia 
marcescens Strain B2. The strain was incubated in LB broth at 28°C with shaking for 72h followed 
by centrifugation (10,000 rpm/5mins) and heat sterilization (2h/60°C) or autoclaving for 20mins. 
The culture supernatant showed potent antifungal activity against soil-borne fungi such as 
Rhizoctonia solani and Fusarium.  
Regarding the thermal stability of the secreted antibacterial activity, Stancu, (2016) reported the 
thermal stability of extracellular secondary metabolites produced by S. marcescens. While 
Bhargavi & Prakasham, (2013) reported the isolation of a macromolecule compound from the 
novel strain Serratia marcescens, RSPB11. This compound showed thermostable properties and 
tolerated temperatures over 60oC. Also, Zarei et al., (2011) isolated a thermo-stable antifungal 
compound from Serratia marcescens B4A. The compound inhibited the growth of plant 
pathogenic fungi such as Rhizoctonia solani and Alternaria species. Besides, anti-insecticidal 
thermostable compounds have been isolated from the culture supernatant of Serratia sp. E-15 and 
Serratia sp. RSPB11 (Wencewicz, 2016; Wu et al., 2016). 
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6.3 Optimization of secreated antibacterial production 
 
When studying antimicrobial secondary metabolites, it is very important to determine the most 
suitable physical factors that enhance their production and resemble their natural environment for 
future utilization and drug development. Culturing parameters can impact the amount and types of 
compounds produced by marine microorganisms. These include cultivation temperatures, aeration, 
incubation time and media composition (Abel et al., 1999; Sa´nchez et al., 2010 b). 
 
6.3.1 Influence of incubation period on the production of secreted antibacterial activity 
 
This study demonstrated a successful optimization of the laboratory parameters that facilitate the 
production of the antibacterial activity by S. plymuthica by studying the influence of different 
growth conditions, incubation period, cultivation temperatures and media composition on the 
production of the secreted activity in the CFCS of the antibacterial producing strain.  
The secreted antibacterial activity can be detected in the CFCS after growing the antibacterial 
producing strain for 24h with highest activity reported btween 48h and 72h (Section 3.2.2) 
resembling the characteristic trait of secondary metabolites. These results are in accordance with 
a study by Jafarzade et al. (2013) that reported the isolation of an antimicrobial compound from 
the marine isolate Serratia sp. WPRA3 after 72h of incubation. The compound showed potent 
antibacterial activity against Gram-positive bacteria. 
 
6.3.2 Influence of cultivation temperatures and media composition on the production of secreted 
antibacterial activity 
 
This study showed that there is a strong link between cultivation temperatures and the production 
of secreted antibacterial activity in the CFCS of S. plymuthica.  
Growing the antibacterial producing strain at 16oC resulted in the production of the highest amount 
of activity detected in the CFCS against the Gram-positive indicator strains in comparison to the 
other cultivation temperatures as previously mentioned in Section 3.2.3. These findings are 
compatible with Sa´nchez et al. (2010 a) who reported the highest amount of antimicrobial activity 
in the culture supernatant of Serratia proteamaculans 136 when the antibacterial producing strain 
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was cultivated at temperatures ranging from (4oC-20oC) while, the lack of antimicrobial activity 
when the strain was cultivated at (30oC–37oC). Another study by Matilla et al. (2016) reported the 
highest amount of antimicrobial activity produced by Serratia A153, when the producer strain was 
cultivated at 15ºC, slightly present when cultivated at 25ºC but completely absent when cultivated 
at 30ºC. Also, Jafarzade et al. (2013) reported the lack of inhibitory activity of Serratia sp. WPRA3 
against S. aureus, B. subtilis and MRSA when the antibacterial producing strain was cultivated at 
32oC.   
The manipulation of culture conditions can be used to improve the secretion of secondary 
metabolites by antibacterial producing strains and the slightest change in growth media 
composition can change the amount of bioactive compounds induced (Reen et al., 2015). 
Regarding the influence of media composition on the production of secreted antibacterial activity, 
results showed media-dependent effects (Section 3.2.3). The highest amount of antibacterial 
activity detected against the Gram-positive strains was from the CFCS obtained from MRS broth. 
These findings are similar to a study by Petersen & Tisa, (2013) who investigated the secondary 
metabolites; bacteriocins and serraticin produced by S. proteamaculans 136. These bioactive 
compounds inhibited the growth of Gram-positive and Gram-negative bacteria. The highest 
amount of antibacterial activity was reported when the antimicrobial producing strain was 
cultivated in rich medium. A study by Aisyah et al. (2016) reported the importance of peptone in 
growth media in triggering the production of antimicrobial activity in some strains of Serratia. 
Another study by Malheiros et al. (2015) reported the significance of MRS broth in enhancing the 
production of antimicrobial compounds by Gram-negative bacteria. 
 
6.3.3 Influence of different growth environments on the production of secreted antibacterial 
activity  
 
The production of secreted antibacterial activity in the CFCS of S. plymuthica is significantly 
affected by cultivation parameters such as aeration and culture vessels (Section 3.2.4). 
Growing the antimicrobial producing strain in 96 well- plates and 50 ml centrifuge tubes produced 
inconsistent results which could be due to the lack of proper aeration. Another possible reason 
could be due to unequal distribution of heat during the heat sterilization step; the 96 well-plate was 
placed in a hot water bath at (70oC/30mins). Also, the relatively small volume of broth medium 
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(~300 µl) in each well left no room for the centrifugation step which is an essential in eliminating 
S. plymuthica cells for the proper detection of the secreted antibacterial activity in the CFCS. On 
the other hand, growing the antibacterial producing strain in 250 ml flasks created a good aerated 
environment for the production of the secreted antibacterial activity. Studies on the antimicrobial 
activity of Serratia, emphasized the importance of sufficient aeration on the maximum production 
of antimicrobial compounds and many used shake-flask fermentations 250 ml flasks to investigate 
the production of antimicrobial activity (Pansuriya & Singhal, 2011; Houdt et al., 2014; Martinez 
et al., 2015). The marine isolate Serratia sp. WPRA3 showed the highest amount of antibacterial 
activity against the Gram-positive strains S. aureus and B. subtilis after the antimicrobial producing 
strain was cultivated for 72h at 200 rev/min (Jafarzade et al., 2013; Shi et al., 2014). 
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6.4 Characterization of secreted antibacterial activity 
 
In order to get a better understanding of the secreted antibacterial activity, the effect of different 
physio-chemical conditions on the stability of the activity was investigated.  
 
6.4.1 Effect of storage on the stability of secreted antibacterial activity 
 
Several studies reported the isolation of cold-active antimicrobial secondary metabolites from 
psychrotrophic bacteria such as; S. proteamaculans 136 and S. liquefaciens (Hemala et al., 2014; 
Machado et al., 2016; Sánchez et al., 2010).  
The effect of storage at 4oC on the stability of the secreted antibacterial activity detected in the 
CFCS was studied by recording the presence of activity against the Gram-positive strain (F). 
Results showed that the activity decreases overtime during storage as previously shown in Table 
3.7 which might indicate that secreted antibacterial compound(s) of S. plymuthica are novel and 
different to other reported Serratia antibacterial compounds.  
 
6.4.2 Effect of Proteinase K, TWEEN® 20 and the pH on the stability of secreted antibacterial 
activity 
 
Several studies reported the isolation of novel Serratia antimicrobial secondary metabolites that 
are insensitive to proteinase K treatment such as the protein antifungal compound produced by 
Serratia marcescens DT. This compound maintained its inhibitory activity towards Rhizoctonia 
solani and Fusarium oxysporum even after treatment with proteinase K (0.5–4 μg/mL) (Do et al., 
2017). Also, Serratia marcescens Mm3 produces a heat-stable bacteriocin antibacterial compound 
that is insensitive to organic solvents and proteinase K (Uğras et al., 2014). 
This study showed that the secreted antibacterial activity was insensitive to proteinase K indicating 
that the antibacterial compound(s) is unlikely to be a protein. Opposite results were reported by 
Valdez et al. (2008) on the loss of antimicrobial activity of the protein toxins of the biocontrol 
agent Serratia entomophila Mor4.1 toward beetle larvae when treated with proteinase K.  
Results also showed that the secreted antibacterial activity remained active after incubation with 
the detergent Tween 20 (Section 3.3.2). Similar results were reported by Li et al. (2011) on the 
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secondary metabolites isolated from the culture supernatant of Serratia sp. SYBC H. The 
compounds showed hydrophilic characteristics and their activity was not inhibited by non-ionic 
detergents like Tween. Regarding the influence of pH on the stability of the secreted antibacterial 
activity, the highest recorded activity was measured at (pH 7.3±0.2) before changing the pH of the 
CFCS. The activity was slightly affected but not inhibited by changes to the pH. These findings 
are similar to numerous studies regarding the pH stability of Serratia secondary metabolites such 
as the antifungal and antimicrobial compounds produced by Serratia marcescens B4A and S. 
proteamaculans (Zarei et al., 2011; Hemala et al., 2014; Solé et al., 2000). 
 
6.4.3 Effect of Tris buffer on the stability of secreted antibacterial activity 
 
The addition of buffers maintains a relatively stable pH during the extraction and purification of 
bacterial secondary metabolites including antimicrobial agents (Thakur et al., 2016; Ahmad & Wu, 
2012; Salarizadeh et al., 2014; Yang et al., 2014). Results showed that the secreted antibacterial 
activity was affected by the addition of Tris-buffer (Section 3.3.4) making it an unsuitable choice 
to be used as a preservative. Further studies are needed to find the optimum medium for the long-
term storage of the secreted activity. 
The results of the NMR spectrometry (Section 5.3) verified the hypothesized precipitation reaction 
produced by S. plymuthica observed in Section 3.3.4, indicating that the secretion of specific 
Serratia enzymes by the antibacterial-producing strain metabolize organic acids and glycerol, 
causing a precipitation reaction; organic acids and glycerol are components of the Tris-buffer and 
NB broth (Newsome et al., 2015; Hejazi & Falkiner, 1997; Ugwu & Apte, 2004). 
 
6.4.4 Molecular weight estimation of the secreted antibacterial compound(s) 
 
Serratia marcescens Strain B2 secretes two antifungal compounds in the culture supernatant. A 
thermo-sensitive high-molecular weight compound and a heat-stable low-molecular weight 
compound (Someya & Kataoka, 2000). Estimation of the molecular weight of the secreted 
antibacterial compound(s) present in the CFCS was done using centrifugal filter units which are 
commonly utilized for the isolation and concentration of bacterial bioactive compounds (Erb et al. 
2010; Paiva et al., 2013). The present study indicates the possible presence of two secreted 
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antibacterial compounds in the CFCS; a compound with a molecular weight ≥10,000 Daltons and 
a compound with a molecular weight >3000 and <10,000 Daltons. It is also possible that there is 
only one antimicrobial compound and that some of it forms larger aggregates. However, results 
obtained via NMR analysis in Section 5.3. contradicts the latter possibility and confirm the 
presence of two antimicrobial compounds in the CFCS.  
Polyketides vary in molecular weight according to functional group modifications (Civjan, 2012). 
Another approach in determining the size of the secreted antimicrobial compounds would be by 
performing gel-filtration chromatography on the CFCS in order to separate and purify the secreted 
antibacterial compounds according to their molecular size (Ó’Fágáin et al., 2011; Hong et al., 
2012; Carbonell et al., 2003; Nawani & Kapadnis, 2001). 
  
6.4.5 The bactericidal activity of the secreted antibacterial compound(s) 
 
Studies reported the production of secreted antimicrobial compounds in the culture supernatant of 
S. marcescens and S. nematodiphila with potent bactericidal activity against E. coli, S. aureus, P. 
aeruginosa, B. subtilis and K. planticola (Malarkodi et al., 2013; Akilandeswari et al., 2014 
Arivizhivendhan et al., 2015). Also, several strains of Serratia produce heat-stable antibacterial 
compounds that are insensitive to proteinase K and active against various Gram-positive bacteria 
such as; B. cereus, B. subtilis and S. aureus (Matilla et al., 2016; Gerc et al., 2012). The novel 
strain, Serratia sp KC149511 isolated from algae possess potent antibacterial and antifungal 
activity (Karthick et al., 2015). Some strains of S. plymuthica produce lytic activity as a protective 
mechanism. These strains produce antimicrobial compounds with broad spectrum antibacterial and 
antifungal properties. An anti-fungal compound was detected in the culture supernatant of a novel 
strain of S. plymuthica when grown in liquid medium for 72h. The compound was thermostable 
and active against Cladosporium and Fusarium (Jankiewicz & Brzezinska, 2015; Frankowski et 
al., 2011). 
Results previously mentioned in Section 3.3.7 showed that the secreted antibacterial compound(s) 
present in the CFCS has species-specific properties, targeting Gram-positive bacteria in particular 
those belonging to Bacillaceae These results are similar to Dusane et al. (2011) who reported the 
antimicrobial activity of the cell-free culture supernatant of the marine bacterium Serratia 
marcescens isolated from the coral Symphyllia. The CFCS inhibited the growth of the Gram-
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positive pathogens; C. albicans and Bacillus pumilus. Gram-positive bacteria are known for their 
susceptibility to antibiotics and antimicrobials due to the lack of the outer lipopolysaccharide 
membrane and porins proteins (Darabpour et al., 2010). 
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6.5 Transposon mutagenesis   
  
Molecular biology methods are important tools for the identification of bacterial genes responsible 
for the production of secondary metabolites (Banik & Brady, 2010; Cragg & Newman, 2013). 
Transposons are mobile genetic elements; segments of DNA that move from one site to another 
on the same genome or different DNA molecules; leading to the disruption of the region of the 
genome where the transposon has been inserted and hence the name (gene knock-out) (Lewenza 
et al., 2005; Judson & Mekalanos, 2000; Bennett, 2008). This creates chromosomal mutations such 
as; DNA insertions, inversions, deletions and chromosomal fusions (Lamberg, 2002; Goryshin et 
al., 2000; Ferrieres et al., 2010; Veeranagouda et al., 2012; Reznikoff, 1993).  
Random transposon mutagenesis inactivates gene function by creating stable single insertions in 
the bacterial host genome as a result of high frequency of transposition and low sequence insertion 
specificity. Transposons are valuable in constructing mutant libraries of strains containing a single 
randomly located transposon based on an observed phenotype whose genotype was disrupted as a 
result of transposon insertion into the genome (Winson et al., 1998; Opijnen & Camilli, 2013; 
Buchan et al., 2008; Reznikoff et al., 1999). 
In this study, transposon mutagenesis was performed via conjugation between the environmental 
strain S. plymuthica and an E. coli strain carrying plasmid pRL27 with the aim of identifying 
gene(s) responsible for the production of the secreted antibacterial activity detected in the CFCS. 
Plasmid pRL27 is a successful transposon delivery vector used with a variety of bacterial species 
including; Xanthobacter autotrophicus, Pseudomonas, E. coli and Citrobacter rodentium (Lyell 
et al., 2008; Choi et al., 2009; Martínez et al., 2014).  
pRL27 is a suicide plasmid and mobilized via the control of the origin of transfer (oriT) from 
plasmid RP4 (Lorenzo et al., 1990; Larsen et al., 2002). During conjugation, the transfer of genetic 
material requires a direct contact between the donor and the recipient cell. A pilus pulls the two 
cells together and a bridge is formed; a single strand of plasmid DNA passes into the recipient cell 
then becomes double stranded (Freeman, 2000; Bruckbauer et al., 2015; Braam et al., 1999).  
The plasmid also carries a mini-Tn5 transposon that encodes resistance to kanamycin KmR and a 
transposase gene (tnp) which is controlled by the tetA promoter (tetAp) from plasmid RP4. The 
tetAp::tnp gene is located outside the transposon so after transposition the tnp gene is lost, leading 
to stable transposon insertions (Naumann & Reznikoff, 2002; Reznikoff et al., 2003; Adams et al., 
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2006). Hence, transposon insertions obtained in this study do not contain the tnp gene and cannot 
induce further transposase-mediated events. They are stable even in the absence of antibiotic 
selection (Hayes, 2003; Hoffman et al., 2000). The Tn5 also contains an origin of replication from 
plasmid R6K (oriR6K) that allows cloning of transposon insertion sites and replication is 
dependent on the π protein encoded by the pir gene. Since S. plymuthica does not contain the π 
protein, KmR transconjugants can only be obtained if the transposon inserts into the recipient 
genome. The transposon insertion with adjacent genomic DNA can be maintained as a plasmid in 
a host with the pir gene; allowing cloning and sequencing of transposon insertion sites (Zhang et 
al., 2000; Ferrieres et al., 2010; Ravindran, 2012; Herrero et al., 1990). 
 
6.5.1 Screening for mutants deficient in the secreted antibacterial activity  
 
While primary bacterial metabolic processes can be found in many bacterial species. Genes 
responsible for the biosynthesis of secondary metabolites are very specialized in which certain 
biochemical pathways are found in restricted bacterial species (Selenko &Wagner, 2007; Strobel 
et al., 1999).  
One might argue that secreted antibacterial activity of the wild type S. plymuthica detected in the 
CFCS is related to the antibacterial activity detected on agar plates. But if this was the case, then 
transposon mutagenesis would only produce one type of mutant that is deficient in both activities; 
(the one identified on agar plates and the one identified in liquid medium). However, this study 
reports the isolation of two KmR transposon mutants; M74 and M426 with phenotypic bioactivity 
opposite to those mutants previously isolated by AlThubiani, (2013). Both KmR transposon 
mutants were deficient in the secreted antibacterial activity but still possessed the antibacterial 
activity detected on agar plates. 
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6.5.2 Identification of transposon insertion sites 
 
Identification of transposon insertion sites was achieved by cloning of transposon insertions. This 
was done by isolating genomic DNA of the KmR transposon-induced mutants M74 and M427, 
followed by enzymatic digestion of the DNA and ligation with T4 DNA ligase. The digested 
genomic DNA of KmR mutants was introduced into an E. coli strain that contains the pir gene so 
that circularized DNA fragments containing the transposon would replicate as pir-dependent 
plasmids. There are various reasons that might have affected the success of transformation in this 
study when using home-made E. coli S17-1 λpir (Section 4.4). The occurrence of few or no 
transformant cells indicate that the competent cells are not sufficiently competent (Zhou et al., 
1998). Another possible reason of transformation failure when using E. coli S17-1 λpir as vectors 
is that, these strains contain the phage Mu genome that can mobilize itself into the recipient cell 
and in turn randomly mutate the recipient genome or even the carried plasmid (Dominguez & 
O’Sullivan, 2013; Tolonen et al., 2006; Strand et al., 2014). Regarding the KmR mutant M74, 
failure to obtain DNA sequencing results from recombinant plasmids could be due to numerous 
reasons; which might have occurred during electroporation that sometimes can cause DNA 
degradation especially when large DNA fragments are cloned in high copy number causing 
illegitimate recombination (Dennis & Zylstra ,1998; Dominguez & O’Sullivan, 2013). Other 
reasons could be due to insufficient or poor DNA quality, presence of contamination in sequencing 
solutions, degraded primers and low concentration of plasmid DNA (Goryshin & Reznikoff, 1998; 
Braam & Reznikoff, 1998). 
  
 6.5.2.1 Microbial biosynthetic pathways  
 
In recent years, the rate of discovery of bioactive compounds has decreased and improved 
screening systems are required to overcome this problem (Komaki et al., 2009; Sakurai et al., 
1996; Akele et al., 2015). The biosynthesis of secondary metabolites remains poorly understood 
across a wide variety of antimicrobial producing species. Also, the number of microbial 
biosynthetic genes greatly exceeds the number of known compounds produced by these 
microorganisms emphasizing the term “silent/cryptic” genes. Research revealed the presence of 
cryptic genes in many anti-microbial producing microorganisms that even with advanced culturing 
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technologies; many remain an untapped source of novel metabolites. This might be due to the fact 
that under laboratory cultivation conditions, these compounds are produced in small amounts that 
cannot easily be detected. Also, biosynthetic genes might not be expressed because their activation 
relies on specific environmental triggers that are missing in laboratory settings (Reen et al., 2015; 
Komaki et al., 2009; Su et al., 2016). This study reports that the secreted antibacterial activity 
detected in the CFCS of the wild type S. plymuthica is synthesized by PKSs that are distinct from 
other known Serratia PKSs. Results of this study are consistent with both suggested possibilities 
of the hypothesis previously mentioned in Section 4.4 in which the antibacterial producing strain 
S. plymuthica might possess separate biochemical pathways leading to two distinct activities or 
have a branched biochemical pathway. However, a knowledge gap still exists between the 
hypothesis and the involvement of PKSs in the production of the observed antibacterial activities. 
Further investigation is absolutely required to realize the full potential of this novel isolate and to 
unveil if the operons responsible for the two activities are in separate genomic locations and 
regulated in different manners which would finally prove that the strain possesses two separate 
biochemical pathways leading to the two distinct activities. Microbial genomics is a rapidly 
developing science to discover novel secondary metabolites for drug discovery. Performing a 
complete genome sequence of S. plymuthica would unlock many unanswered questions and reveal 
valuable insights regarding genes functions and regulations (Chung et al., 2013; Li et al., 2015; 
Bachmann, 2014). 
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6.6 Purification of the secreted antibacterial compound(s) by organic solvent extraction 
 
 In microbiological samples, antimicrobial compounds usually represent <1% of the original 
mixture and studying these compounds begins by extraction from crude samples followed by 
purification and identification (Peláez, 2006; Penesyan, 2010).  
In this study, purification of the secreted antibacterial compound(s) was preceded by concentrating 
the CFCS via freeze drying. Freeze-drying can be used to effectively dry microbiological samples 
including those containing antimicrobial compounds through dehydration and sublimation of ice 
without affecting the integrity of the compounds of interest. This method also prevents microbial 
growth and hence might improve the storage stability of some bioactive compounds (Shofian et 
al., 2011; Mphahlele et al., 2016; Perry, 1998). 
Regarding the solubility of secreted antibacterial compound(s) in methanol (Section 5.2). Several 
studies reported the solubility of Serratia antibacterial compounds in water and organic solvents 
(Li et al., 2011; UĞRAŞ et al., 2014; Pore et al., 2016) including the secreted compounds in 
Serratia sp. SYBC H culture supernatant and the thermostable secondary metabolites of Serratia 
marcescens (Kaira et al., 2015; Hejazi & Falkiner, 1997).  
The secreted antibacterial compound(s) detected in the CFCS of the wild type Serratia plymuthica 
resembles the peptide antibiotic marcescin isolated from the culture supernatant of S. marcescens 
(Fuller & Horton, 1950). Both compounds are thermostable, bactericidal and inhibit the growth of 
Gram-positive bacteria and their production is influenced by aeration and temperatures below 
25oC. Both compounds are soluble in water and organic solvents and their antimicrobial activity 
fades after few days even when stored at low temperatures (0-4oC). Also, both compounds tend to 
precipitate when solvent is added forming a voluminous jelly.  
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6.7 NMR and COSY NMR spectroscopy  
 
NMR spectroscopy allows structural investigations at the atomic level and is efficient in analyzing 
complex biological mixtures such as culture supernatants of microbial cultures and in the detection 
and identification of low molecular-weight metabolites even at low concentrations (AlMajidi, 
2014; Pegos et al., 2014; Gerwick & Fenner, 2013; Kwon et al., 2014; Gouda et al., 2010).  
NMR is a rapid, high-throughput analysis technique, accurate and non-destructive with minimal 
sample preparation; no necessity for purification of compounds from original mixtures (Brennan, 
2014; Fan & Lane, 2016; Bharti & Roy, 2012; Singh & Pheko, 2008). Likewise, COSY NMR is a 
sensitive, rapid, automated analytical technique used for the detection of coupling interactions of 
unknown natural secondary metabolites in order to identify their molecular structure. The COSY 
spectrum encompasses an NMR spectrum that runs across a diagonal ridge from the upper right 
corner to the lower right corner of the plot. Each axis is calibrated based on the chemical shift 
values (ppm). In COSY NMR, the identification of unknown compounds can be achieved via their 
spin–spin couplings manifested by distinctive cross peak patterns (Kempgens & Pinchuck, 2016; 
Winden et al., 2001; Xi et al., 2007).  
In this study, results of NMR and COSY NMR spectroscopy showed that the CFCS contains a 
secondary metabolite resembling the antibacterial antibiotic erythromycin produced by 6-
deoxyerythronolide B synthases (DEBS) which are large multifunctional enzymes belonging to 
type I PKSs (Sanchez et al., 2010 b; Pereda et al.,1998; Mcdaniel et al.,1999). Results also showed 
the presence of another antibacterial compound in the CFCS with similarities to rapamycin 
indicated by the presence of double bonds at the 7-9 ppm region of the NMR spectrum (Section 
5.3). Polyketides produced by type I PKSs such as erythromycin and rapamycin are used as anti-
bacterial and immune-suppressant compounds (Cane, 2010). Both erythromycin and rapamycin 
are macrolide antibiotics and protein synthesis inhibitors. Erythromycin can be used to treat 
respiratory tract infections such as; bronchitis, pneumonia. Rapamycin is an immunosuppressant 
prevents organ transplant rejection (Bedford et al., 1996; Hill et al.,2017; Li et al., 2014) 
PKSs are responsible for the biosynthesis of polyketides which are a large and diverse class of 
natural products created via the condensation and modification of carboxylic acids and involve 
different enzymatic functions (Crosby & Crump, 2012; Tyc et al., 2017; Shelest et al., 2015). For 
many years now, PKSs of bacterial origins have been shown to be responsible for the production 
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of various novel secondary metabolites (Zhang et al., 2009). There have been numerous studies 
regarding marine derived polyketides, but much remains to be done in characterizing marine 
microbial PKSs and understanding their associated biological functions (O'Connor, 2015; 
Penesyan, 2010; Staunton & Weissman, 2001). PKSs are arranged in clusters in bacterial genomes 
and are responsible for the biosynthesis of numerous diverse secondary metabolites many of which 
are used as anti-cancers and antibiotics (Donadio et al., 2007; Masschelein et al., 2015a). 
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6.8 Conclusion and future work: 
 
6.8.1 Conclusion: 
 
Serratia species synthesize a diverse array of secondary metabolites with unique biological 
properties and represent a promising valuable source for research and understanding the 
biochemical nature of these compounds is the key for future development of new drugs and 
antibiotics. Results of this study concluded the following: 
 1- To our knowledge, this is the first study regarding an environmental isolate of S. plymuthica 
capable of producing two antibacterial activities both encoding PKSs.  
2-Different cultivation parameters such as; culture medium, aeration and temperature have a clear 
impact on the production of the secreted antibacterial activity detected in the CFCS which might 
help in future large-scale production of the antimicrobial compounds.  
3- The secreted antibacterial activity was thermo-stable and remained active even after sterilization 
(121°C/15mins). 
4- The secreted antibacterial activity was insensitive to methanol, Proteinase K, Tween and pH 
and therefore has potential in industrial and environmental biotechnology, food industry, and 
bioremediation. 
5- The secreted antibacterial activity was bactericidal and a promising antibacterial agent against 
some Gram-positive bacteria.  
6- The secreted antibacterial activity fades after few days even when stored at (4oC) and 
precipitates in the presences of solvents. 
7- NMR and COSY NMR spectroscopy showed that the CFCS contains two secondary metabolites 
resembling the antibiotics erythromycin and rapamycin produced by DEBS. 
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6.8.2 Future work: 
 
Modern medicine relies heavily on antibiotics to combat bacterial infections. Antibiotic resistance 
is a serious threat to humanity and a challenge to modern medical practices. Many countries and 
international agencies around the world have implemented numerous policies to hinder the spread 
of antibiotic resistance in clinical practices and in the community. The development of new 
antimicrobial compounds is urgently needed before the current antibiotics used in clinical settings 
become compromised by antibiotic resistance. The range of Serratia species is vast and produces 
an enormous group of secondary metabolites with different unique bioactive compounds and 
provide an excellent basis for investigation for future drug discovery and the expansion of the 
pharmaceutical pipeline. Many bacterial species encompass PKS genes however, many are not 
expressed under normal laboratory conditions. Despite the extensive research in the field of 
microbial secondary metabolites, knowledge of the structure and function of many polyketides 
still remains a mystery. Further studies are needed for the molecular characterization and 
purification of the secreted antibacterial compounds present in the CFCS as well as the 
identification of other secondary metabolites that might be produced by this novel strain of S. 
plymuthica to unveil any underlying biosynthetic pathways which might reveal the presence of 
new compounds with future importance.  
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